{"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405345","label":"url"}],"paper_title":{"en":"Raman Microspectroscopy for Label-Free Diagnosis of Amyloid Light-chain Amyloidosis in Various Organs","ja":"Raman Microspectroscopy for Label-Free Diagnosis of Amyloid Light-chain Amyloidosis in Various Organs"},"authors":{"en":[{"name":"Yanagiya Shin-ichiro"},{"name":"Honda Takeshi"},{"name":"Takanari Hiroki"},{"name":"Sogabe Kimiko"},{"name":"Nakamura Shingen"},{"name":"Bando Yoshimi"},{"name":"Abe Masahiro"},{"name":"Miki Hirokazu"}],"ja":[{"name":"柳谷 伸一郎"},{"name":"本田 剛士"},{"name":"髙成 広起"},{"name":"曽我部 公子"},{"name":"中村 信元"},{"name":"坂東 良美"},{"name":"安倍 正博"},{"name":"三木 浩和"}]},"publication_date":"2024-02","publication_name":{"en":"Journal of Raman Spectroscopy","ja":"Journal of Raman Spectroscopy"},"languages":["eng"],"referee":true,"identifiers":{"issn":["0377-0486"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38245883","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405470","label":"url"}],"paper_title":{"en":"Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.","ja":"Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors."},"authors":{"en":[{"name":"Sogabe Kimiko"},{"name":"Nakamura Shingen"},{"name":"Higa Yoshiki"},{"name":"Miki Hirokazu"},{"name":"Oda Asuka"},{"name":"Maruhashi Tomoko"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Takahashi Mamiko"},{"name":"Nakamura Masafumi"},{"name":"Maeda Yusaku"},{"name":"Hara Tomoyo"},{"name":"Yamagami Hiroki"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Kurahashi Kiyoe"},{"name":"Endo Itsuro"},{"name":"Aihara Ken-ichi"},{"name":"Nakaue Emiko"},{"name":"Hiasa Masahiro"},{"name":"Teramachi Jumpei"},{"name":"Harada Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"曽我部 公子"},{"name":"中村 信元"},{"name":"比嘉 佳基"},{"name":"三木 浩和"},{"name":"Oda Asuka"},{"name":"丸橋 朋子"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"Takahashi Mamiko"},{"name":"中村 昌史"},{"name":"前田 悠作"},{"name":"原 倫世"},{"name":"山上 紘規"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"尾崎 修治"},{"name":"倉橋 清衛"},{"name":"遠藤 逸朗"},{"name":"粟飯原 賢一"},{"name":"中上 絵美子"},{"name":"日浅 雅博"},{"name":"寺町 順平"},{"name":"原田 武志"},{"name":"安倍 正博"}]},"description":{"en":"Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs.","ja":"Resistance to proteasome inhibitors (PIs) has emerged as an important clinical issue. We investigated the mechanisms underlying multiple myeloma (MM) cell resistance to PIs. To mimic their pharmacokinetic/pharmacodynamic (PK/PD) profiles, MM cells were treated with bortezomib and carfilzomib for 1 h at concentrations up to 400 and 1,000 nM, respectively. Susceptibility to these PIs markedly varied among MM cell lines. Pulsatile treatments with PIs suppressed translation, as demonstrated by incorporation of puromycin at 24 h in PI-susceptible MM.1S cells, but not PI-resistant KMS-11 cells. Inhibition of β5 subunit activity decreased at 24 h in KMS-11 cells, even with the irreversible PI carfilzomib, but not under suppression of protein synthesis with cycloheximide. Furthermore, the proteasome-degradable pro-survival factors PIM2 and NRF2 acutely accumulated in MM cells subjected to pulsatile PI treatments. Accumulated NRF2 was trans-localized into the nucleus to induce the expression of its target gene, HMOX1, in MM cells. PIM and Akt inhibition restored the anti-MM effects of PIs, even against PI-resistant KMS-11 cells. Collectively, these results suggest that increased synthesis of β5 proteasome subunit and acute accumulation of PIM2 and NRF2 reduce the anti-MM effects of PIs."},"publication_date":"2024-01-21","publication_name":{"en":"International journal of hematology","ja":"International journal of hematology"},"volume":"Vol.119","number":"No.3","starting_page":"303","ending_page":"315","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-023-03705-9"],"issn":["1865-3774"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/118211","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36129197","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396173","label":"url"}],"paper_title":{"en":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase","ja":"Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase"},"authors":{"en":[{"name":"Harada Takeshi"},{"name":"Ohguchi Hiroto"},{"name":"Oda Asuka"},{"name":"Nakao Michiyasu"},{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Maruhashi Tomoko"},{"name":"Takahashi Mamiko"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Sano Shigeki"},{"name":"Hideshima Teru"},{"name":"Abe Masahiro"}],"ja":[{"name":"原田 武志"},{"name":"大口 裕人"},{"name":"小田 明日香"},{"name":"中尾 允泰"},{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"丸橋 朋子"},{"name":"高橋 真美子"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"尾崎 修治"},{"name":"佐野 茂樹"},{"name":"秀島 輝"},{"name":"安倍 正博"}]},"description":{"en":"Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM.","ja":"Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM."},"publication_date":"2023-03-28","publication_name":{"en":"Blood Advances","ja":"Blood Advances"},"volume":"Vol.7","number":"No.6","starting_page":"1019","ending_page":"1032","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1182/bloodadvances.2022007155"],"issn":["2473-9537"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36856824","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=395910","label":"url"}],"paper_title":{"en":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.","ja":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents."},"authors":{"en":[{"name":"Teramachi Jumpei"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Hiasa Masahiro"},{"name":"Harada Takeshi"},{"name":"Abe Masahiro"}],"ja":[{"name":"寺町 順平"},{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"日浅 雅博"},{"name":"原田 武志"},{"name":"安倍 正博"}]},"description":{"en":"MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents.","ja":"MM cells produce a variety of cytokines to stimulate receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis and suppress osteoblastic differentiation from bone marrow stromal cells, leading to extensive bone destruction with rapid loss of bone. MM cells alter the microenvironment through bone destruction where they colonize, which in turn favors tumor growth and survival, thereby forming a vicious cycle between tumor progression and bone destruction. Denosumab or zoledronic acid is currently recommended to be administered at the start of treatment in newly diagnosed patients with MM with bone disease. Proteasome inhibitors and the anti-CD38 monoclonal antibody daratumumab have been demonstrated to exert bone-modifying activity in responders. Besides their anti-tumor activity, the effects of new anti-MM agents on bone metabolism should be more precisely analyzed in patients with MM. Because prognosis in patients with MM has been significantly improved owing to the implementation of new agents, the therapeutic impact of bone-modifying agents should be re-estimated in the era of these new agents."},"publication_date":"2023-03-01","publication_name":{"en":"Journal of Bone and Mineral Metabolism","ja":"Journal of Bone and Mineral Metabolism"},"starting_page":"1","ending_page":"16","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00774-023-01403-4"],"issn":["1435-5604"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://repo.lib.tokushima-u.ac.jp/117969","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050295181679877760/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402576","label":"url"}],"paper_title":{"en":"徳島県におけるHIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題","ja":"徳島県におけるHIV感染症および後天性免疫不全症候群患者の臨床的特徴と今後の課題"},"authors":{"en":[{"name":"高原 由実子"},{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"林 成樹"},{"name":"Sumitani Ryohei"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"髙橋 真美子"},{"name":"丸橋 朋子"},{"name":"富永 誠記"},{"name":"岡本 秀樹"},{"name":"Okada Naoto"},{"name":"矢野 由美子"},{"name":"高橋 真理"},{"name":"大坂 朱美"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Suge Toshiyuki"},{"name":"Aota Keiko"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"}],"ja":[{"name":"高原 由実子"},{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"林 成樹"},{"name":"住谷 龍平"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"髙橋 真美子"},{"name":"丸橋 朋子"},{"name":"富永 誠記"},{"name":"岡本 秀樹"},{"name":"岡田 直人"},{"name":"矢野 由美子"},{"name":"高橋 真理"},{"name":"大坂 朱美"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"菅 俊行"},{"name":"青田 桂子"},{"name":"尾崎 修治"},{"name":"安倍 正博"}]},"description":{"en":"【Introduction】The survival rate in patients with HIV infection and acquired immunodeficiency syndrome (AIDS) has been improved dramatically due to the advances in anti-HIV drug therapy, while aging-associated complications become a critical issue. The incidence of sudden occurrence of AIDS without prior detection of HIV infection, so called ``Ikinari AIDS'', still remains high. 【Objective】We retrospectively analyzed the incidence and clinical characteristics of HIV/AIDS patients in both Tokushima University Hospital and Tokushima Prefectural Central Hospital. 【Results】Eighty four patients (74 males and 10 females) with a median age of 39 years old (range 16 - 85) were enrolled. Thirty-four patients (40.5%) were diagnosed with ``Ikinari AIDS'' from 2001 to 2020. All 4 patients were diagnosed with ``Ikinari AIDS'' after 2020. AIDS-defining illnesses were diagnosed as follows ; pneumocystis pneumonia in 21 cases, CMV infection in 8 cases and candidiasis in 6 cases. All patients over 60 years old were suffered from AIDS. Other complications included syphilis in 17 cases, hepatitis B infection in 12 and herpes zoster in 7. 【Discussion/Conclusion】In Tokushima, the incidence rate of ``Ikinari AIDS'' appeared to be higher than that of national average. COVID - 19 pandemic hampered the public health care services of awareness-raising activity for HIV infection and telephone consultations about HIV, which may become more lease asymptomatic HIV patients without diagnosis. For early diagnosis of HIV/AIDS, it is becoming more important to share information to make early screening of HIV infection among medical staffs, such as medical doctors, dentists, nurses, pharmacists and MSWs.","ja":"【Introduction】The survival rate in patients with HIV infection and acquired immunodeficiency syndrome (AIDS) has been improved dramatically due to the advances in anti-HIV drug therapy, while aging-associated complications become a critical issue. The incidence of sudden occurrence of AIDS without prior detection of HIV infection, so called ``Ikinari AIDS'', still remains high. 【Objective】We retrospectively analyzed the incidence and clinical characteristics of HIV/AIDS patients in both Tokushima University Hospital and Tokushima Prefectural Central Hospital. 【Results】Eighty four patients (74 males and 10 females) with a median age of 39 years old (range 16 - 85) were enrolled. Thirty-four patients (40.5%) were diagnosed with ``Ikinari AIDS'' from 2001 to 2020. All 4 patients were diagnosed with ``Ikinari AIDS'' after 2020. AIDS-defining illnesses were diagnosed as follows ; pneumocystis pneumonia in 21 cases, CMV infection in 8 cases and candidiasis in 6 cases. All patients over 60 years old were suffered from AIDS. Other complications included syphilis in 17 cases, hepatitis B infection in 12 and herpes zoster in 7. 【Discussion/Conclusion】In Tokushima, the incidence rate of ``Ikinari AIDS'' appeared to be higher than that of national average. COVID - 19 pandemic hampered the public health care services of awareness-raising activity for HIV infection and telephone consultations about HIV, which may become more lease asymptomatic HIV patients without diagnosis. For early diagnosis of HIV/AIDS, it is becoming more important to share information to make early screening of HIV infection among medical staffs, such as medical doctors, dentists, nurses, pharmacists and MSWs."},"publication_date":"2022-12-25","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.78","number":"No.5-6","starting_page":"193","ending_page":"198","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117583","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35752658","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386499","label":"url"}],"paper_title":{"en":"A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy","ja":"A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy"},"authors":{"en":[{"name":"Yamada Hiroki"},{"name":"Ohmori Rio"},{"name":"Okada Naoto"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Ishizawa Keisuke"},{"name":"Abe Masahiro"},{"name":"Sato Youichi"}],"ja":[{"name":"山田 博貴"},{"name":"大森 理央"},{"name":"Okada Naoto"},{"name":"中村 信元"},{"name":"Kagawa Kumiko"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"石澤 啓介"},{"name":"安倍 正博"},{"name":"佐藤 陽一"}]},"description":{"en":"Vincristine treatment may cause peripheral neuropathy. In this study, we identified the genes associated with the development of peripheral neuropathy due to vincristine therapy using a genome-wide association study (GWAS) and constructed a predictive model for the development of peripheral neuropathy using genetic information-based machine learning. The study included 72 patients admitted to the Department of Hematology, Tokushima University Hospital, who received vincristine. Of these, 56 were genotyped using the Illumina Asian Screening Array-24 Kit, and a GWAS for the onset of peripheral neuropathy caused by vincristine was conducted. Using Sanger sequencing for 16 validation samples, the top three single nucleotide polymorphisms (SNPs) associated with the onset of peripheral neuropathy were determined. Machine learning was performed using the statistical software R package \"caret\". The 56 GWAS and 16 validation samples were used as the training and test sets, respectively. Predictive models were constructed using random forest, support vector machine, naive Bayes, and neural network algorithms. According to the GWAS, rs2110179, rs7126100, and rs2076549 were associated with the development of peripheral neuropathy on vincristine administration. Machine learning was performed using these three SNPs to construct a prediction model. A high accuracy of 93.8% was obtained with the support vector machine and neural network using rs2110179 and rs2076549. Thus, peripheral neuropathy development due to vincristine therapy can be effectively predicted by a machine learning prediction model using SNPs associated with it.","ja":"Vincristine treatment may cause peripheral neuropathy. In this study, we identified the genes associated with the development of peripheral neuropathy due to vincristine therapy using a genome-wide association study (GWAS) and constructed a predictive model for the development of peripheral neuropathy using genetic information-based machine learning. The study included 72 patients admitted to the Department of Hematology, Tokushima University Hospital, who received vincristine. Of these, 56 were genotyped using the Illumina Asian Screening Array-24 Kit, and a GWAS for the onset of peripheral neuropathy caused by vincristine was conducted. Using Sanger sequencing for 16 validation samples, the top three single nucleotide polymorphisms (SNPs) associated with the onset of peripheral neuropathy were determined. Machine learning was performed using the statistical software R package \"caret\". The 56 GWAS and 16 validation samples were used as the training and test sets, respectively. Predictive models were constructed using random forest, support vector machine, naive Bayes, and neural network algorithms. According to the GWAS, rs2110179, rs7126100, and rs2076549 were associated with the development of peripheral neuropathy on vincristine administration. Machine learning was performed using these three SNPs to construct a prediction model. A high accuracy of 93.8% was obtained with the support vector machine and neural network using rs2110179 and rs2076549. Thus, peripheral neuropathy development due to vincristine therapy can be effectively predicted by a machine learning prediction model using SNPs associated with it."},"publication_date":"2022-06-25","publication_name":{"en":"The Pharmacogenomics Journal","ja":"The Pharmacogenomics Journal"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41397-022-00282-8"],"issn":["1473-1150"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35534187","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394086","label":"url"}],"paper_title":{"en":"Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength.","ja":"Allogeneic haematopoietic stem cell transplantation and patient falls: impact of lower extremity muscle strength."},"authors":{"en":[{"name":"Kondo Shin"},{"name":"Inoue Tatsuro"},{"name":"Saito Takashi"},{"name":"Kawamura Yuka"},{"name":"Katayama Ayane"},{"name":"Nakamura Masafumi"},{"name":"Sumitani Ryohei"},{"name":"Takahashi Mamiko"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Sato Nori"},{"name":"Ono Rei"},{"name":"Abe Masahiro"},{"name":"Katoh Shinsuke"}],"ja":[{"name":"Kondo Shin"},{"name":"Inoue Tatsuro"},{"name":"Saito Takashi"},{"name":"Kawamura Yuka"},{"name":"Katayama Ayane"},{"name":"Nakamura Masafumi"},{"name":"住谷 龍平"},{"name":"Takahashi Mamiko"},{"name":"大浦 雅博"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"佐藤 紀"},{"name":"Ono Rei"},{"name":"安倍 正博"},{"name":"加藤 真介"}]},"description":{"en":"Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT.","ja":"Pretransplant LEMS was a significant predictor of post-transplant falls. The results of this study may help to prevent falls in patients undergoing allo-HSCT."},"publication_date":"2022-05-09","publication_name":{"en":"BMJ Supportive & Palliative Care","ja":"BMJ Supportive & Palliative Care"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bmjspcare-2022-003582"],"issn":["2045-4368"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117584","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34657909","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383649","label":"url"}],"paper_title":{"en":"A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment","ja":"A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment"},"authors":{"en":[{"name":"Takei Minori"},{"name":"Okada Naoto"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Ishizawa Keisuke"},{"name":"Abe Masahiro"},{"name":"Sato Youichi"}],"ja":[{"name":"武井 みのり"},{"name":"Okada Naoto"},{"name":"中村 信元"},{"name":"賀川 久美子"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"石澤 啓介"},{"name":"安倍 正博"},{"name":"佐藤 陽一"}]},"description":{"en":"Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs.","ja":"Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs."},"publication_date":"2022-01-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"Vol.45","number":"No.1","starting_page":"114","ending_page":"117","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b21-00745"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://repo.lib.tokushima-u.ac.jp/117140","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050855267567099520/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387553","label":"url"}],"paper_title":{"en":"徳島大学病院における先天性血友病患者(成人例)の実態調査∼移行期医療の重要性∼","ja":"徳島大学病院における先天性血友病患者(成人例)の実態調査∼移行期医療の重要性∼"},"authors":{"en":[{"name":"西條 早希"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"谷口 早紀"},{"name":"岡本 秀樹"},{"name":"富永 誠記"},{"name":"Okada Naoto"},{"name":"矢野 由美子"},{"name":"髙橋 真理"},{"name":"Aota Keiko"},{"name":"Suge Toshiyuki"},{"name":"Watanabe Hiroyoshi"},{"name":"大坂 朱美"},{"name":"Abe Masahiro"}],"ja":[{"name":"西條 早希"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"谷口 早紀"},{"name":"岡本 秀樹"},{"name":"富永 誠記"},{"name":"岡田 直人"},{"name":"矢野 由美子"},{"name":"髙橋 真理"},{"name":"青田 桂子"},{"name":"菅 俊行"},{"name":"渡邊 浩良"},{"name":"大坂 朱美"},{"name":"安倍 正博"}]},"description":{"en":"【Introduction】Congenital hemophilia is a category of hemorrhagic disease caused by a genetic defect in the production of coagulation factors. It is treated by administering regular coagulation factor injections on an ongoing basis. Hemophilia is a hereditary illness, often causing social and psychological problems as a result of the disease. To analyze the objective effects of hemophilia, we conducted a retrospective analysis in Tokushima University Hospital. 【Result】All 23 cases were men between the ages of20and72. Hemophilia A was present in17cases, and hemophilia B was present in six. Nineteen out of 23 cases were severe, and the others were intermediate. Medical assessments were conducted at pediatrics in seven cases and hematology in 16 cases. Adoption of the self-injection technique was not realized in five cases. Seventeen cases were complicated by hemophilic arthropathy, seven with human immunodeficiency virus(HIV), and 12 with hepatitis C virus. Eight participants were unemployed, and17were unmarried. 【Discussion】 Many adult hemophilia patients still visit pediatrics in our hospital. Hemophilia in the period of growth between adolescence and young adulthood is often accompanied by life-altering events such as entering higher education, marriage, and work experience. Therefore, collaboration among professionals of multiple occupations, such as doctors, nurses, pharmacists, medical social workers, and clinical psychologists, is essential. Furthermore, there are many cases of HIV and hepatitis C virus infections complicating hemophilia study due to the stigma surrounding HIV-tainted blood. 【Conclusion】It is imperative that we establish a long-term, sustainable, and multi-disciplinary transitional care and medical support system for patients and their families.","ja":"【Introduction】Congenital hemophilia is a category of hemorrhagic disease caused by a genetic defect in the production of coagulation factors. It is treated by administering regular coagulation factor injections on an ongoing basis. Hemophilia is a hereditary illness, often causing social and psychological problems as a result of the disease. To analyze the objective effects of hemophilia, we conducted a retrospective analysis in Tokushima University Hospital. 【Result】All 23 cases were men between the ages of20and72. Hemophilia A was present in17cases, and hemophilia B was present in six. Nineteen out of 23 cases were severe, and the others were intermediate. Medical assessments were conducted at pediatrics in seven cases and hematology in 16 cases. Adoption of the self-injection technique was not realized in five cases. Seventeen cases were complicated by hemophilic arthropathy, seven with human immunodeficiency virus(HIV), and 12 with hepatitis C virus. Eight participants were unemployed, and17were unmarried. 【Discussion】 Many adult hemophilia patients still visit pediatrics in our hospital. Hemophilia in the period of growth between adolescence and young adulthood is often accompanied by life-altering events such as entering higher education, marriage, and work experience. Therefore, collaboration among professionals of multiple occupations, such as doctors, nurses, pharmacists, medical social workers, and clinical psychologists, is essential. Furthermore, there are many cases of HIV and hepatitis C virus infections complicating hemophilia study due to the stigma surrounding HIV-tainted blood. 【Conclusion】It is imperative that we establish a long-term, sustainable, and multi-disciplinary transitional care and medical support system for patients and their families."},"publication_date":"2021-12-25","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.77","number":"No.5-6","starting_page":"261","ending_page":"268","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34949601","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=394089","label":"url"}],"paper_title":{"en":"Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength.","ja":"Allogeneic haematopoietic stem cell transplantation-clinical outcomes: impact of leg muscle strength."},"authors":{"en":[{"name":"Kondo Shin"},{"name":"Kagawa Kumiko"},{"name":"Saito Takashi"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Sato Nori"},{"name":"Ono Rei"},{"name":"Abe Masahiro"},{"name":"Katoh Shinsuke"}],"ja":[{"name":"Kondo Shin"},{"name":"Kagawa Kumiko"},{"name":"Saito Takashi"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"佐藤 紀"},{"name":"Ono Rei"},{"name":"安倍 正博"},{"name":"加藤 真介"}]},"description":{"en":"Pre-transplant LEMS was a significant factor in predicting OS and NRM.","ja":"Pre-transplant LEMS was a significant factor in predicting OS and NRM."},"publication_date":"2021-12-23","publication_name":{"en":"BMJ Supportive & Palliative Care","ja":"BMJ Supportive & Palliative Care"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1136/bmjspcare-2021-003256"],"issn":["2045-4368"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34567945","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386279","label":"url"}],"paper_title":{"en":"Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation","ja":"Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation"},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Miyamoto Ryosuke"},{"name":"Shima Kasane"},{"name":"Miki Hirokazu"},{"name":"Terasawa Hideo"},{"name":"Takasu Chie"},{"name":"Yoshikawa Kouzou"},{"name":"Oyama Takuro"},{"name":"Tanaka Katsuya"},{"name":"Izumi Yuishin"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"宮本 亮介"},{"name":"Shima Kasane"},{"name":"三木 浩和"},{"name":"Terasawa Hideo"},{"name":"髙須 千絵"},{"name":"吉川 幸造"},{"name":"Oyama Takuro"},{"name":"Tanaka Katsuya"},{"name":"和泉 唯信"},{"name":"島田 光生"}]},"description":{"en":"Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Although affected patients may develop cancers, major surgical intervention has been hampered by its questionable overall benefit due to limited prognosis and risk of postoperative respiratory collapse. A recent study, however, showed that tracheostomy invasive ventilation (TIV) prolonged median survival to 11.3 years; thus, patients with ALS receiving TIV might benefit from major surgery. A 66-year-old man with ALS, who had received TIV and enteral tube feeding for 8 years, presented with bloody stool. The patient also had type 2 diabetes mellitus, stage 4 chronic kidney disease, abdominal aortic aneurysm, and anti-phospholipid syndrome, as well as multiple episodes of pneumonia and catheter-related urinary tract infection treated by antibiotics. Medical examination and esophagogastroduodenoscopy revealed a type 3 tumor in the middle part of the stomach. The patient's preoperative diagnosis was gastric cancer (GC), MU, type3, Less-Post, T3(SS), N1, H0, P0, M0, cStage III. The estimated mortality rate was 30.5%, according to the Japanese National Clinical Database. The patient and his family were fully informed of the risk of surgery; the patient clearly requested curative surgery by eye movement. Thus, robot-assisted total gastrectomy (RATG) was performed. The tissues were extremely fragile and hemorrhagic. The surgical time was 7 h 0 min; intraoperative blood loss was 324 ml. Pathological examination revealed GC, MU, type3, T4a(SE), N2, H0, CY0, P0, M0 fStage IIIB. The postoperative course was uneventful. He has remained in stable condition for 3 months. Our findings suggest that patients with ALS who achieve longer survival with TIV can undergo major cancer surgery, including robot-assisted surgery, which may facilitate a better mid-long-term prognosis. The online version contains supplementary material available at 10.1007/s13691-021-00499-7.","ja":"Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease. Although affected patients may develop cancers, major surgical intervention has been hampered by its questionable overall benefit due to limited prognosis and risk of postoperative respiratory collapse. A recent study, however, showed that tracheostomy invasive ventilation (TIV) prolonged median survival to 11.3 years; thus, patients with ALS receiving TIV might benefit from major surgery. A 66-year-old man with ALS, who had received TIV and enteral tube feeding for 8 years, presented with bloody stool. The patient also had type 2 diabetes mellitus, stage 4 chronic kidney disease, abdominal aortic aneurysm, and anti-phospholipid syndrome, as well as multiple episodes of pneumonia and catheter-related urinary tract infection treated by antibiotics. Medical examination and esophagogastroduodenoscopy revealed a type 3 tumor in the middle part of the stomach. The patient's preoperative diagnosis was gastric cancer (GC), MU, type3, Less-Post, T3(SS), N1, H0, P0, M0, cStage III. The estimated mortality rate was 30.5%, according to the Japanese National Clinical Database. The patient and his family were fully informed of the risk of surgery; the patient clearly requested curative surgery by eye movement. Thus, robot-assisted total gastrectomy (RATG) was performed. The tissues were extremely fragile and hemorrhagic. The surgical time was 7 h 0 min; intraoperative blood loss was 324 ml. Pathological examination revealed GC, MU, type3, T4a(SE), N2, H0, CY0, P0, M0 fStage IIIB. The postoperative course was uneventful. He has remained in stable condition for 3 months. Our findings suggest that patients with ALS who achieve longer survival with TIV can undergo major cancer surgery, including robot-assisted surgery, which may facilitate a better mid-long-term prognosis. The online version contains supplementary material available at 10.1007/s13691-021-00499-7."},"publication_date":"2021-07-12","publication_name":{"en":"International Cancer Conference Journal","ja":"International Cancer Conference Journal"},"volume":"Vol.10","number":"No.4","starting_page":"318","ending_page":"323","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s13691-021-00499-7"],"issn":["2192-3183"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116529","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32273474","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=377110","label":"url"}],"paper_title":{"en":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma","ja":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma"},"authors":{"en":[{"name":"Teramachi Jumpei"},{"name":"Tenshin Hirofumi"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Harada Takeshi"},{"name":"Nakamura Shingen"},{"name":"Ashtar Mohannad"},{"name":"Shimizu Sou"},{"name":"Iwasa Masami"},{"name":"Sogabe Kimiko"},{"name":"Oura Masahiro"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Miki Hirokazu"},{"name":"Endo Itsuro"},{"name":"Haneji Tatsuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"寺町 順平"},{"name":"天眞 寛文"},{"name":"日浅 雅博"},{"name":"小田 明日香"},{"name":"Ariunzaya Bat-Erdene"},{"name":"原田 武志"},{"name":"中村 信元"},{"name":"ASHTAR MOHANNAD"},{"name":"清水 宗"},{"name":"岩佐 昌美"},{"name":"曽我部 公子"},{"name":"大浦 雅博"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"三木 浩和"},{"name":"遠藤 逸朗"},{"name":"羽地 達次"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM.","ja":"Along with the tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-β-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. We demonstrate here that TAK1 is constitutively overexpressed and phosphorylated in MM cells, and that TAK1 inhibition suppresses the activation of NF-κB, p38MAPK, ERK and STAT3 to decrease the expression of critical mediators for MM growth and survival, including PIM2, MYC, Mcl-1, IRF4, and Sp1, along with a substantial reduction in the angiogenic factor VEGF in MM cells. Intriguingly, TAK1 phosphorylation was also induced along with upregulation of vascular cell adhesion molecule-1 (VCAM-1) in bone marrow stromal cells (BMSCs) in cocultures with MM cells, which facilitated MM cell-BMSC adhesion while inducing IL-6 production and receptor activator of nuclear factor κ-Β ligand (RANKL) expression by BMSCs. TAK1 inhibition effectively impaired MM cell adhesion to BMSCs to disrupt the support of MM cell growth and survival by BMSCs. Furthermore, TAK1 inhibition suppressed osteoclastogenesis enhanced by RANKL in cocultures of bone marrow cells with MM cells, and restored osteoblastic differentiation suppressed by MM cells or inhibitory factors for osteoblastogenesis overproduced in MM. Finally, treatment with the TAK1 inhibitor LLZ1640-2 markedly suppressed MM tumor growth and prevented bone destruction and loss in mouse MM models. Therefore, TAK1 inhibition may be a promising therapeutic option targeting not only MM cells but also the skewed bone marrow microenvironment in MM."},"publication_date":"2021-05-01","publication_name":{"en":"Haematologica","ja":"Haematologica"},"volume":"Vol.106","number":"No.5","starting_page":"1401","ending_page":"1413","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3324/haematol.2019.234476"],"issn":["1592-8721"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2021171647","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1391694356262403200/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391687","label":"url"}],"paper_title":{"en":"A case of congenital prekallikrein deficiency discovered by preoperative screening","ja":"術前スクリーニングで偶然発見された先天性プレカリクレイン欠乏症の1症例"},"authors":{"en":[{"name":"SUGASAKI Motoki"},{"name":"TOKUNAGA Naoki"},{"name":"IKEGAME Akishige"},{"name":"NAKAO Takayuki"},{"name":"Oura Masahiro"},{"name":"Miki Hirokazu"},{"name":"Nagai Kojiro"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"菅﨑 幹樹"},{"name":"徳永 尚樹"},{"name":"池亀 彰茂"},{"name":"中尾 隆之"},{"name":"大浦 雅博"},{"name":"三木 浩和"},{"name":"長井 幸二郎"},{"name":"高山 哲治"}]},"publication_date":"2021-01-25","publication_name":{"en":"Japanese Journal of Medical Technology","ja":"医学検査"},"volume":"Vol.70","number":"No.1","starting_page":"132","ending_page":"137","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.14932/jamt.20-5"],"issn":["0915-8669"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116536","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33456032","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=379404","label":"url"}],"paper_title":{"en":"Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis.","ja":"Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis."},"authors":{"en":[{"name":"Sumitani Ryohei"},{"name":"Hori Taiki"},{"name":"Murai Jumpei"},{"name":"Kawata Shiyori"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Takahashi Mamiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Abe Masahiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"住谷 龍平"},{"name":"Hori Taiki"},{"name":"Murai Jumpei"},{"name":"Kawata Shiyori"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"Takahashi Mamiko"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"安倍 正博"},{"name":"中村 信元"}]},"description":{"en":"A 33-year-old man was admitted to our hospital for fever and abdominal pain. A blood analysis revealed pancytopenia and increased serum pancreatic enzymes with disseminated intravascular coagulation. A detailed examination revealed acute pancreatitis, with diffuse swelling of the pancreas and diffuse beaded dilatation of the main pancreatic duct, which mimicked autoimmune pancreatitis complicated by acute myeloid leukemia. Systemic cytotoxic chemotherapy led to the remission of leukemia and pancreatitis. We hypothesized that the etiology of acute pancreatitis was invasion of leukemia cells. Acute pancreatitis is rare as a symptom of leukemia; however, we should consider the possibility of leukemia during the differential diagnosis of acute pancreatitis.","ja":"A 33-year-old man was admitted to our hospital for fever and abdominal pain. A blood analysis revealed pancytopenia and increased serum pancreatic enzymes with disseminated intravascular coagulation. A detailed examination revealed acute pancreatitis, with diffuse swelling of the pancreas and diffuse beaded dilatation of the main pancreatic duct, which mimicked autoimmune pancreatitis complicated by acute myeloid leukemia. Systemic cytotoxic chemotherapy led to the remission of leukemia and pancreatitis. We hypothesized that the etiology of acute pancreatitis was invasion of leukemia cells. Acute pancreatitis is rare as a symptom of leukemia; however, we should consider the possibility of leukemia during the differential diagnosis of acute pancreatitis."},"publication_date":"2021-01-15","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"volume":"Vol.60","number":"No.11","starting_page":"1753","ending_page":"1757","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.4916-20"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/117585","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=383725","label":"url"}],"paper_title":{"en":"Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor","ja":"Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor"},"authors":{"en":[{"name":"Hozumi Tashima"},{"name":"Yuka Endo"},{"name":"Okada Naoto"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Ishizawa Keisuke"},{"name":"Abe Masahiro"},{"name":"Sato Youichi"}],"ja":[{"name":"田島 穂澄"},{"name":"遠藤 優香"},{"name":"岡田 直人"},{"name":"中村 信元"},{"name":"賀川 久美子"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"石澤 啓介"},{"name":"安倍 正博"},{"name":"佐藤 陽一"}]},"publication_date":"2021","publication_name":{"en":"Personalized Medicine Universe","ja":"Personalized Medicine Universe"},"volume":"Vol.10","starting_page":"1","ending_page":"6","languages":["eng"],"referee":true,"identifiers":{"doi":["10.46459/pmu.2021002"],"issn":["2186-4950"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116021","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33994471","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=379403","label":"url"}],"paper_title":{"en":"Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.","ja":"Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement."},"authors":{"en":[{"name":"Takahashi Mamiko"},{"name":"Sumitani Ryohei"},{"name":"Hori Taiki"},{"name":"Murai Jumpei"},{"name":"Kawata Shiyori"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Abe Masahiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"Takahashi Mamiko"},{"name":"住谷 龍平"},{"name":"Hori Taiki"},{"name":"Murai Jumpei"},{"name":"Kawata Shiyori"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"安倍 正博"},{"name":"中村 信元"}]},"description":{"en":"The prognosis of relapsed or refractory lymphoma with central nervous system (CNS) involvement remains poor because of the lack of anticancer drugs with sufficient CNS penetration. [Case 1] A 65-year-old man was diagnosed with Stage IV mantle cell lymphoma. After two courses of chemotherapy and autologous hematopoietic stem cell (HSC) collection, urinary retention with fever developed. Cerebrospinal fluid analysis revealed leptomeningeal involvement, which was refractory to high-dose methotrexate therapy. Autologous peripheral blood stem cell transplantation (ASCT) was performed, followed by intravenous busulfan (ivBU), cyclophosphamide, and etoposide ; thereafter, no relapse has been detected for over six years. [Case 2] A 40-year-old woman with right lower hemiplegia was diagnosed with primary CNS lymphoma. Although four courses of high-dose methotrexate therapy were administered, the cerebral tumor increased in size. HSCs were collected after methotrexate therapy, and ASCT was performed in addition to conditioning using ivBU, cyclophosphamide, and etoposide, followed by whole-brain and local boost irradiation. She achieved complete remission, but relapsed two years after ASCT. High-dose ivBU-containing conditioning regimens with ASCT may be useful for refractory B-cell lymphoma with CNS involvement. J. Med. Invest. 68 : 196-201, February, 2021.","ja":"The prognosis of relapsed or refractory lymphoma with central nervous system (CNS) involvement remains poor because of the lack of anticancer drugs with sufficient CNS penetration. [Case 1] A 65-year-old man was diagnosed with Stage IV mantle cell lymphoma. After two courses of chemotherapy and autologous hematopoietic stem cell (HSC) collection, urinary retention with fever developed. Cerebrospinal fluid analysis revealed leptomeningeal involvement, which was refractory to high-dose methotrexate therapy. Autologous peripheral blood stem cell transplantation (ASCT) was performed, followed by intravenous busulfan (ivBU), cyclophosphamide, and etoposide ; thereafter, no relapse has been detected for over six years. [Case 2] A 40-year-old woman with right lower hemiplegia was diagnosed with primary CNS lymphoma. Although four courses of high-dose methotrexate therapy were administered, the cerebral tumor increased in size. HSCs were collected after methotrexate therapy, and ASCT was performed in addition to conditioning using ivBU, cyclophosphamide, and etoposide, followed by whole-brain and local boost irradiation. She achieved complete remission, but relapsed two years after ASCT. High-dose ivBU-containing conditioning regimens with ASCT may be useful for refractory B-cell lymphoma with CNS involvement. J. Med. Invest. 68 : 196-201, February, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.68","number":"No.1.2","starting_page":"196","ending_page":"201","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.68.196"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85090482286&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=379841","label":"url"}],"paper_title":{"en":"Near-Infrared Fluorescent Thiol-Organosilica Nanoparticles That Are Functionalized with IR-820 and Their Applications for Long-Term Imaging of in Situ Labeled Cells and Depth-Dependent Tumor in Vivo Imaging","ja":"Near-Infrared Fluorescent Thiol-Organosilica Nanoparticles That Are Functionalized with IR-820 and Their Applications for Long-Term Imaging of in Situ Labeled Cells and Depth-Dependent Tumor in Vivo Imaging"},"authors":{"en":[{"name":"Nakamura Michihiro"},{"name":"Hayashi Koichiro"},{"name":"Nakamura Junna"},{"name":"Mochizuki Chihiro"},{"name":"Murakami Takuya"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"}],"ja":[{"name":"Nakamura Michihiro"},{"name":"Hayashi Koichiro"},{"name":"Nakamura Junna"},{"name":"Mochizuki Chihiro"},{"name":"Murakami Takuya"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"}]},"publication_date":"2020-08","publication_name":{"en":"Chemistry of Materials","ja":"Chemistry of Materials"},"volume":"Vol.32","number":"No.17","starting_page":"7201","ending_page":"7214","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1021/acs.chemmater.0c01414"],"issn":["0897-4756"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115041","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32283857","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=365352","label":"url"}],"paper_title":{"en":"The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.","ja":"The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat."},"authors":{"en":[{"name":"Ashtar Mohannad"},{"name":"Tenshin Hirofumi"},{"name":"Teramachi Jumpei"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Tanimoto Kotaro"},{"name":"Shimizu Sou"},{"name":"Higa Yoshiki"},{"name":"Harada Takeshi"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Nakamura Shingen"},{"name":"Fujii Shiroh"},{"name":"Sumitani Ryohei"},{"name":"Miki Hirokazu"},{"name":"Udaka Kengo"},{"name":"Takahashi Mamiko"},{"name":"Kagawa Kumiko"},{"name":"Endo Itsuro"},{"name":"Tanaka Eiji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"ASHTAR MOHANNAD"},{"name":"天眞 寛文"},{"name":"寺町 順平"},{"name":"Ariunzaya Bat-Erdene"},{"name":"日浅 雅博"},{"name":"Oda Asuka"},{"name":"谷本 幸多朗"},{"name":"清水 宗"},{"name":"比嘉 佳基"},{"name":"原田 武志"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"中村 信元"},{"name":"藤井 志朗"},{"name":"住谷 龍平"},{"name":"三木 浩和"},{"name":"宇髙 憲吾"},{"name":"Takahashi Mamiko"},{"name":"賀川 久美子"},{"name":"遠藤 逸朗"},{"name":"田中 栄二"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox's anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage.","ja":"Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox's anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage."},"publication_date":"2020-04-09","publication_name":{"en":"Cancers","ja":"Cancers"},"volume":"Vol.12","number":"No.4","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/cancers12040929"],"issn":["2072-6694"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115047","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31861479","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85077198248&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=364706","label":"url"}],"paper_title":{"en":"Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma","ja":"Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma"},"authors":{"en":[{"name":"Ozaki Shuji"},{"name":"Harada Takeshi"},{"name":"Yagi Hikaru"},{"name":"Sekimoto Etsuko"},{"name":"Shibata Hironobu"},{"name":"Shigekiyo Toshio"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Abe Masahiro"}],"ja":[{"name":"尾崎 修治"},{"name":"原田 武志"},{"name":"Yagi Hikaru"},{"name":"Sekimoto Etsuko"},{"name":"Shibata Hironobu"},{"name":"Shigekiyo Toshio"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"安倍 正博"}]},"description":{"en":"We retrospectively analyzed multiple myeloma (MM) patients who underwent autologous stem cell transplantation (ASCT) without maintenance therapy to assess the impact of recovery of normal immunoglobulin (Ig) on clinical outcomes. The recovery of polyclonal Ig was defined as normalization of all values of serum IgG, IgA, and IgM 1 year after ASCT. Among 50 patients, 26 patients showed polyclonal Ig recovery; 14 patients were in ≥complete response (CR) and 12 remained in non-CR after ASCT. The patients with Ig recovery exhibited a significantly better progression-free survival (PFS, median, 46.8 vs 26.7 months, = 0.0071) and overall survival (OS, median, not reached vs 65.3 months, < 0.00001) compared with those without Ig recovery. The survival benefits of Ig recovery were similarly observed in ≥CR patients (median OS, not reached vs 80.5 months, = 0.061) and non-CR patients (median OS, not reached vs 53.2 months, = 0.00016). Multivariate analysis revealed that non-CR and not all Ig recovery were independent prognostic factors for PFS (HR, 4.284, 95%CI (1.868-9.826), = 0.00059; and HR, 2.804, 95%CI (1.334-5.896), = 0.0065, respectively) and also for OS (HR, 8.245, 95%CI (1.528-44.47), = 0.014; and HR, 36.55, 95%CI (3.942-338.8), = 0.0015, respectively). Therefore, in addition to the depth of response, the recovery of polyclonal Ig after ASCT is a useful indicator especially for long-term outcome and might be considered to prevent overtreatment with maintenance therapy in transplanted patients with MM.","ja":"We retrospectively analyzed multiple myeloma (MM) patients who underwent autologous stem cell transplantation (ASCT) without maintenance therapy to assess the impact of recovery of normal immunoglobulin (Ig) on clinical outcomes. The recovery of polyclonal Ig was defined as normalization of all values of serum IgG, IgA, and IgM 1 year after ASCT. Among 50 patients, 26 patients showed polyclonal Ig recovery; 14 patients were in ≥complete response (CR) and 12 remained in non-CR after ASCT. The patients with Ig recovery exhibited a significantly better progression-free survival (PFS, median, 46.8 vs 26.7 months, = 0.0071) and overall survival (OS, median, not reached vs 65.3 months, < 0.00001) compared with those without Ig recovery. The survival benefits of Ig recovery were similarly observed in ≥CR patients (median OS, not reached vs 80.5 months, = 0.061) and non-CR patients (median OS, not reached vs 53.2 months, = 0.00016). Multivariate analysis revealed that non-CR and not all Ig recovery were independent prognostic factors for PFS (HR, 4.284, 95%CI (1.868-9.826), = 0.00059; and HR, 2.804, 95%CI (1.334-5.896), = 0.0065, respectively) and also for OS (HR, 8.245, 95%CI (1.528-44.47), = 0.014; and HR, 36.55, 95%CI (3.942-338.8), = 0.0015, respectively). Therefore, in addition to the depth of response, the recovery of polyclonal Ig after ASCT is a useful indicator especially for long-term outcome and might be considered to prevent overtreatment with maintenance therapy in transplanted patients with MM."},"publication_date":"2019-12-18","publication_name":{"en":"Cancers","ja":"Cancers"},"volume":"Vol.12","number":"No.1","starting_page":"12","ending_page":"12","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3390/cancers12010012"],"issn":["2072-6694"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115842","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31911987","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85079442682&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=367316","label":"url"}],"paper_title":{"en":"Improvement of global longitudinal strain following high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with amyloid light-chain cardiac amyloidosis: a case report.","ja":"Improvement of global longitudinal strain following high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with amyloid light-chain cardiac amyloidosis: a case report."},"authors":{"en":[{"name":"Hirata Yukina"},{"name":"Kusunose Kenya"},{"name":"Miki Hirokazu"},{"name":"Yamada Hirotsugu"}],"ja":[{"name":"Hirata Yukina"},{"name":"楠瀬 賢也"},{"name":"三木 浩和"},{"name":"山田 博胤"}]},"description":{"en":"Cardiac amyloidosis (CA) is a secondary form of cardiomyopathy where abnormal accumulation of amyloid protein in the myocardial interstitium causes cardiac hypertrophy and myocardial fibrosis. If primary CA advances to heart failure, most patients do not survive for very long after the diagnosis. A 40-year-old man was admitted to our hospital for dyspnoea, progressive anaemia, and decreased appetite. He has diagnosed with amyloid light-chain (AL) amyloidosis. Although BD treatment (bortezomib + dexamethasone) and medical treatment were started, there was no sign of improvement. Then, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) was initiated. Pretreatment echocardiography revealed typical findings of CA, such as ventricular wall thickening, valvular thickening, diastolic dysfunction, and pericardial effusion. Global longitudinal strain (GLS) was significantly reduced, and bull's-eye mapping showed typical apical sparing. After auto-PBSCT, GLS gradually improved and was almost normal after 2 years. Other echocardiographic parameters, functional status, and laboratory data also showed that there was significant regression of CA. Although the prognosis in primary CA is extremely poor, we achieved long-term survival in a patient with effective high-dose chemotherapy and auto-PBSCT. Global longitudinal strain may be a useful marker of prognosis, regression, and recovery.","ja":"Cardiac amyloidosis (CA) is a secondary form of cardiomyopathy where abnormal accumulation of amyloid protein in the myocardial interstitium causes cardiac hypertrophy and myocardial fibrosis. If primary CA advances to heart failure, most patients do not survive for very long after the diagnosis. A 40-year-old man was admitted to our hospital for dyspnoea, progressive anaemia, and decreased appetite. He has diagnosed with amyloid light-chain (AL) amyloidosis. Although BD treatment (bortezomib + dexamethasone) and medical treatment were started, there was no sign of improvement. Then, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) was initiated. Pretreatment echocardiography revealed typical findings of CA, such as ventricular wall thickening, valvular thickening, diastolic dysfunction, and pericardial effusion. Global longitudinal strain (GLS) was significantly reduced, and bull's-eye mapping showed typical apical sparing. After auto-PBSCT, GLS gradually improved and was almost normal after 2 years. Other echocardiographic parameters, functional status, and laboratory data also showed that there was significant regression of CA. Although the prognosis in primary CA is extremely poor, we achieved long-term survival in a patient with effective high-dose chemotherapy and auto-PBSCT. Global longitudinal strain may be a useful marker of prognosis, regression, and recovery."},"publication_date":"2019-12-16","publication_name":{"en":"European Heart Journal. Case Reports","ja":"European Heart Journal. Case Reports"},"volume":"Vol.3","number":"No.4","starting_page":"1","ending_page":"6","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/ehjcr/ytz225"],"issn":["2514-2119"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31511938","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361040","label":"url"}],"paper_title":{"en":"Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.","ja":"Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study."},"authors":{"en":[{"name":"Okada Naoto"},{"name":"Chuma Masayuki"},{"name":"Azuma Momoyo"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Hamano Hirofumi"},{"name":"Goda Mitsuhiro"},{"name":"Takechi Kenshi"},{"name":"Zamami Yoshito"},{"name":"Abe Masahiro"},{"name":"Ishizawa Keisuke"}],"ja":[{"name":"岡田 直人"},{"name":"中馬 真幸"},{"name":"東 桃代"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"Hamano Hirofumi"},{"name":"合田 光寛"},{"name":"武智 研志"},{"name":"座間味 義人"},{"name":"安倍 正博"},{"name":"石澤 啓介"}]},"description":{"en":"We retrospectively analysed 150 haematologic patients to whom VCM was administered between April 2010 and March 2018 at Tokushima University Hospital. VCM-induced AKI was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression analyses were performed to identify risk factors for VCM-induced AKI.","ja":"The optimal initial VCM trough concentration was 10-15 mg/L in haematologic patients, considering safety and effectiveness. There were differences in the effect of VCM-induced AKI between nephrotoxic drugs."},"publication_date":"2019-09-11","publication_name":{"en":"European Journal of Clinical Pharmacology","ja":"European Journal of Clinical Pharmacology"},"volume":"Vol.75","number":"No.12","starting_page":"1695","ending_page":"1704","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00228-019-02756-4"],"issn":["1432-1041"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113359","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30956773","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85062760316&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351838","label":"url"}],"paper_title":{"en":"PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.","ja":"PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ."},"authors":{"en":[{"name":"Iwasa Masami"},{"name":"Harada Takeshi"},{"name":"Oda Asuka"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Teramachi Jumpei"},{"name":"Tenshin Hirofumi"},{"name":"Ashtar Mohannad"},{"name":"Oura Masahiro"},{"name":"Sogabe Kimiko"},{"name":"Udaka Kengo"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"}],"ja":[{"name":"Iwasa Masami"},{"name":"原田 武志"},{"name":"Oda Asuka"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Teramachi Jumpei"},{"name":"天眞 寛文"},{"name":"Ashtar Mohannad"},{"name":"大浦 雅博"},{"name":"曽我部 公子"},{"name":"宇髙 憲吾"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"}]},"description":{"en":"gene silencing abolished the PD-L1 upregulation by panobinostat and IFN-γ in combination, indicating a critical role for STAT1. These results suggest that panobinostat enhances PD-L1 expression by facilitating the IFN-γ-STAT1 pathway in a ligand-dependent manner in MM cells with ambient IFN-γ. PD-L1 upregulation should be taken into account when combining immunotherapies with panobinostat.","ja":"gene silencing abolished the PD-L1 upregulation by panobinostat and IFN-γ in combination, indicating a critical role for STAT1. These results suggest that panobinostat enhances PD-L1 expression by facilitating the IFN-γ-STAT1 pathway in a ligand-dependent manner in MM cells with ambient IFN-γ. PD-L1 upregulation should be taken into account when combining immunotherapies with panobinostat."},"publication_date":"2019-03-08","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"Vol.10","number":"No.20","starting_page":"1903","ending_page":"1917","languages":["eng"],"referee":true,"identifiers":{"doi":["10.18632/oncotarget.26726"],"issn":["1949-2553"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/120006552370/","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112987","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050845763422780928/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=358522","label":"url"}],"paper_title":{"en":"De novo CD 20-negative diffuse large B-cell lymphoma developed with sustained fever and markedly high C-reactive protein level","ja":"不明熱と著明な高CRP血症で発症したde novo CD20陰性びまん性大細胞型B細胞リンパ腫の1例"},"authors":{"en":[{"name":"Miyakami Yuko"},{"name":"Nakamura Shingen"},{"name":"Oura Masahiro"},{"name":"Okamoto Yasunobu"},{"name":"高橋 真美子"},{"name":"Sogabe Kimiko"},{"name":"岩佐 昌美"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Uehara Hisanori"},{"name":"Abe Masahiro"}],"ja":[{"name":"宮上 侑子"},{"name":"中村 信元"},{"name":"大浦 雅博"},{"name":"岡本 惠暢"},{"name":"高橋 真美子"},{"name":"曽我部 公子"},{"name":"岩佐 昌美"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"上原 久典"},{"name":"安倍 正博"}]},"description":{"en":"A 68-year-old woman presented with sustained fever for more than 1 month and admitted due to hematemesis and systemic edema. Computed tomography scan revealed swelling of the cervical, paraaortic lymph nodes. Blood test results showed severe anemia, elevation of white blood cell count, elevation of liver enzyme and coagulopathy with high C-reactive protein. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells with necrosis and hemorrhage, which are positive for CD79α, CD30, MUM-1, and bcl-6 and negative for CD20, CD5, CD10, ALK, CD38, CD138, and EBER. Gene rearrangement of immunoglobulin heavy chain was detected in tumor cells. Bone marrow aspiration showed tumor involvement. The patient was diagnosed with de novo CD20-negative diffuse large B-cell lymphoma(DLBCL)stage IV B. Reduced CHOP therapy was performed under artificial respiration due to pulmonary edema and takotsubo cardiomyopathy. Although her general condition and high CRP levels temporarily improved, she died 47 days after admission due to rapid relapse. De novo CD20-negative DLBCL was rare and presented with high CRP levels and rapid progression, and was thought to be clinically different from the existing DLBCL. It is imperative to elucidate molecular pathophysiology and establish new treatment strategy for de novo CD20-negative DLBCL.","ja":"A 68-year-old woman presented with sustained fever for more than 1 month and admitted due to hematemesis and systemic edema. Computed tomography scan revealed swelling of the cervical, paraaortic lymph nodes. Blood test results showed severe anemia, elevation of white blood cell count, elevation of liver enzyme and coagulopathy with high C-reactive protein. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells with necrosis and hemorrhage, which are positive for CD79α, CD30, MUM-1, and bcl-6 and negative for CD20, CD5, CD10, ALK, CD38, CD138, and EBER. Gene rearrangement of immunoglobulin heavy chain was detected in tumor cells. Bone marrow aspiration showed tumor involvement. The patient was diagnosed with de novo CD20-negative diffuse large B-cell lymphoma(DLBCL)stage IV B. Reduced CHOP therapy was performed under artificial respiration due to pulmonary edema and takotsubo cardiomyopathy. Although her general condition and high CRP levels temporarily improved, she died 47 days after admission due to rapid relapse. De novo CD20-negative DLBCL was rare and presented with high CRP levels and rapid progression, and was thought to be clinically different from the existing DLBCL. It is imperative to elucidate molecular pathophysiology and establish new treatment strategy for de novo CD20-negative DLBCL."},"publication_date":"2018-12-25","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.74","number":"No.5-6","starting_page":"193","ending_page":"200","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113393","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30474853","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85057280798&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=348588","label":"url"}],"paper_title":{"en":"Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.","ja":"Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA."},"authors":{"en":[{"name":"Bat-Erdene Ariunzaya"},{"name":"Nakamura Shingen"},{"name":"Oda Asuka"},{"name":"Iwasa Masami"},{"name":"Teramachi Jumpei"},{"name":"Ashtar Mohannad"},{"name":"Harada Takeshi"},{"name":"Miki Hirokazu"},{"name":"Tenshin Hirofumi"},{"name":"Hiasa Masahiro"},{"name":"Fujii Shiroh"},{"name":"Sogabe Kimiko"},{"name":"Oura Masahiro"},{"name":"Udaka Kengo"},{"name":"Kagawa Kumiko"},{"name":"Yoshida Sumiko"},{"name":"Aihara Ken-ichi"},{"name":"Kurahashi Kiyoe"},{"name":"Endo Itsuro"},{"name":"Abe Masahiro"}],"ja":[{"name":"Bat-Erdene Ariunzaya"},{"name":"中村 信元"},{"name":"Oda Asuka"},{"name":"Iwasa Masami"},{"name":"寺町 順平"},{"name":"Ashtar Mohannad"},{"name":"原田 武志"},{"name":"三木 浩和"},{"name":"天眞 寛文"},{"name":"日浅 雅博"},{"name":"藤井 志朗"},{"name":"曽我部 公子"},{"name":"大浦 雅博"},{"name":"Udaka Kengo"},{"name":"賀川 久美子"},{"name":"吉田 守美子"},{"name":"粟飯原 賢一"},{"name":"倉橋 清衛"},{"name":"遠藤 逸朗"},{"name":"安倍 正博"}]},"publication_date":"2018-11-26","publication_name":{"en":"British Journal of Haematology","ja":"British Journal of Haematology"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/bjh.15673"],"issn":["1365-2141"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/114401","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30101939","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=338434","label":"url"}],"paper_title":{"en":"A case of Lambda Light Chain Noncrystalline Proximal Tubulopathy with IgD lambda myeloma","ja":"A case of Lambda Light Chain Noncrystalline Proximal Tubulopathy with IgD lambda myeloma"},"authors":{"en":[{"name":"Kishi Seiji"},{"name":"小幡 史明"},{"name":"Miki Hirokazu"},{"name":"Matsuura Motokazu"},{"name":"Tamaki Masanori"},{"name":"Kishi Fumi"},{"name":"西村 賢二"},{"name":"Murakami Taichi"},{"name":"Abe Hideharu"},{"name":"Nagai Kojiro"},{"name":"Abe Masahiro"},{"name":"Doi Toshio"}],"ja":[{"name":"岸 誠司"},{"name":"小幡 史明"},{"name":"三木 浩和"},{"name":"松浦 元一"},{"name":"田蒔 昌憲"},{"name":"岸 史"},{"name":"西村 賢二"},{"name":"村上 太一"},{"name":"安部 秀斉"},{"name":"長井 幸二郎"},{"name":"安倍 正博"},{"name":"土井 俊夫"}]},"publication_date":"2018-05-07","publication_name":{"en":"Internal Medicine","ja":"Internal Medicine"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.2169/internalmedicine.1323-18"],"issn":["1349-7235"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115817","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29277954","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85041047530&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345049","label":"url"}],"paper_title":{"en":"Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies.","ja":"Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies."},"authors":{"en":[{"name":"Kagawa Kumiko"},{"name":"Fujino Hikaru"},{"name":"Miki Hirokazu"},{"name":"Sogabe Kimiko"},{"name":"Takahashi Mamiko"},{"name":"Maruhashi Tomoko"},{"name":"Udaka Kengo"},{"name":"Iwasa Masami"},{"name":"Fujii Shiro"},{"name":"Nakamura Shingen"},{"name":"Abe Masahiro"}],"ja":[{"name":"賀川 久美子"},{"name":"藤野 ひかる"},{"name":"三木 浩和"},{"name":"曽我部 公子"},{"name":"髙橋 真美子"},{"name":"Maruhashi Tomoko"},{"name":"Udaka Kengo"},{"name":"Iwasa Masami"},{"name":"Fujii Shiro"},{"name":"Nakamura Shingen"},{"name":"安倍 正博"}]},"description":{"en":"Disseminated Cryptosporidium infection results in manifestations similar to those of graft-versus-host disease (GVHD), which hampers the detection of Cryptosporidium infection after allogeneic hematopoietic stem cell transplantation. Surveillance of oocysts on the surface of intestinal epithelial cells is needed for early and appropriate detection of Cryptosporidium infection in transplant recipients on immunosuppressants with severe intractable diarrhea. We present the first case of Cryptosporidium meleagridis infection in Japan after allogeneic cord blood transplantation.","ja":"Disseminated Cryptosporidium infection results in manifestations similar to those of graft-versus-host disease (GVHD), which hampers the detection of Cryptosporidium infection after allogeneic hematopoietic stem cell transplantation. Surveillance of oocysts on the surface of intestinal epithelial cells is needed for early and appropriate detection of Cryptosporidium infection in transplant recipients on immunosuppressants with severe intractable diarrhea. We present the first case of Cryptosporidium meleagridis infection in Japan after allogeneic cord blood transplantation."},"publication_date":"2018-04","publication_name":{"en":"Transplant Infectious Disease","ja":"Transplant Infectious Disease"},"volume":"Vol.20","number":"No.2","starting_page":"e12826","ending_page":"e12826","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/tid.12826"],"issn":["1399-3062"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112935","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27748523","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=321702","label":"url"}],"paper_title":{"en":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.","ja":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma."},"authors":{"en":[{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Harada Takeshi"},{"name":"Nakamura Shingen"},{"name":"Amachi Ryota"},{"name":"Tenshin Hirofumi"},{"name":"Iwasa Masami"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Miki Hirokazu"},{"name":"Kurahashi Kiyoe"},{"name":"Yoshida Sumiko"},{"name":"Endo Itsuro"},{"name":"Haneji Tatsuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"Oda Asuka"},{"name":"Harada Takeshi"},{"name":"中村 信元"},{"name":"天知 良太"},{"name":"天眞 寛文"},{"name":"Iwasa Masami"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"三木 浩和"},{"name":"倉橋 清衛"},{"name":"吉田 守美子"},{"name":"遠藤 逸朗"},{"name":"羽地 達次"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"publication_date":"2018-02-17","publication_name":{"en":"British Journal of Haematology","ja":"British Journal of Haematology"},"volume":"Vol.180","number":"No.4","starting_page":"581","ending_page":"585","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/bjh.14388"],"issn":["1365-2141"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112752","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29327347","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85040344893&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341053","label":"url"}],"paper_title":{"en":"Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.","ja":"Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity."},"authors":{"en":[{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Oda Asuka"},{"name":"Miki Hirokazu"},{"name":"Tenshin Hirofumi"},{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Maeda Yusaku"},{"name":"Oura Masahiro"},{"name":"Takahashi Mamiko"},{"name":"Iwasa Masami"},{"name":"Endo Itsuro"},{"name":"Yoshida Sumiko"},{"name":"Aihara Ken-ichi"},{"name":"Kurahashi Kiyoe"},{"name":"Harada Takeshi"},{"name":"Kagawa Kumiko"},{"name":"Nakao Michiyasu"},{"name":"Sano Shigeki"},{"name":"Abe Masahiro"}],"ja":[{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"Oda Asuka"},{"name":"三木 浩和"},{"name":"天眞 寛文"},{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Maeda Yusaku"},{"name":"大浦 雅博"},{"name":"Takahashi Mamiko"},{"name":"Iwasa Masami"},{"name":"遠藤 逸朗"},{"name":"吉田 守美子"},{"name":"粟飯原 賢一"},{"name":"倉橋 清衛"},{"name":"原田 武志"},{"name":"賀川 久美子"},{"name":"中尾 允泰"},{"name":"佐野 茂樹"},{"name":"安倍 正博"}]},"description":{"en":"Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of different types of PIM inhibitors against MM cells for their possible clinical application. Intriguingly, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a reduced PIM2 protein levels and impaired MM cell survival preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. SMI-16a also suppressed the drug efflux function of breast cancer resistance protein, minimized the sizes of side populations and reduced in vitro colony-forming capacity and in vivo tumourigenic activity in MM cells, suggesting impairment of their clonogenic capacity. PIM2 is known to be subject to ubiquitination-independent proteasomal degradation. Consistent with this, the proteasome inhibitors bortezomib and carfilzomib increased PIM2 protein levels in MM cells without affecting its mRNA levels. However, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects in combination with carfilzomib. Collectively, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein in MM cells, which may contribute to their profound efficacy in addition to their immediate kinase inhibition. Their combination with proteasome inhibitors is envisioned.","ja":"Proviral Integrations of Moloney virus 2 (PIM2) is overexpressed in multiple myeloma (MM) cells, and regarded as an important therapeutic target. Here, we aimed to validate the therapeutic efficacy of different types of PIM inhibitors against MM cells for their possible clinical application. Intriguingly, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a reduced PIM2 protein levels and impaired MM cell survival preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. SMI-16a also suppressed the drug efflux function of breast cancer resistance protein, minimized the sizes of side populations and reduced in vitro colony-forming capacity and in vivo tumourigenic activity in MM cells, suggesting impairment of their clonogenic capacity. PIM2 is known to be subject to ubiquitination-independent proteasomal degradation. Consistent with this, the proteasome inhibitors bortezomib and carfilzomib increased PIM2 protein levels in MM cells without affecting its mRNA levels. However, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects in combination with carfilzomib. Collectively, the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein in MM cells, which may contribute to their profound efficacy in addition to their immediate kinase inhibition. Their combination with proteasome inhibitors is envisioned."},"publication_date":"2018-01","publication_name":{"en":"British Journal of Haematology","ja":"British Journal of Haematology"},"volume":"Vol.180","number":"No.2","starting_page":"246","ending_page":"258","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/bjh.15033"],"issn":["1365-2141"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/40021456242/","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112059","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050001338847982080/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=345095","label":"url"}],"paper_title":{"en":"Development of adult T-cell leukemia/lymphoma during immunosuppressive Therapy for human T-cell leukemia virus type 1 associated arthropathy","ja":"リウマチ様関節炎に対する免疫抑制療法中に発症した成人T細胞性白血病/リンパ腫の1例"},"authors":{"en":[{"name":"山口 純代"},{"name":"Nakamura Shingen"},{"name":"住田 智志"},{"name":"前田 悠作"},{"name":"Oura Masahiro"},{"name":"高橋 真美子"},{"name":"岩佐 昌美"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Kishi Jun"},{"name":"Abe Masahiro"}],"ja":[{"name":"山口 純代"},{"name":"中村 信元"},{"name":"住田 智志"},{"name":"前田 悠作"},{"name":"大浦 雅博"},{"name":"高橋 真美子"},{"name":"岩佐 昌美"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"岸 潤"},{"name":"安倍 正博"}]},"description":{"en":"A 64-year-old woman presented with lower leg edema, fever, and bilateral joint pain, involving the wrists, fingers, and knees, in April 201X. Serological test results were negative for rheumatoid factor, antinuclear antibody, and anti-cyclic citrullinated peptide antibody. A diagnosis of remitting seronegative symmetrical synovitis with pitting edema syndrome, a type of seronegative rheumatoid arthritis, was made and prednisolone was administered. The joint pain was refractory to prednisolone therapy. In February, 201X+2, the patient presented with right cervical lymphadenopathy. The CT scan revealed swelling of the cervical, axillary, and inguinal lymph nodes bilaterally and rapidly enlarged. In April, 18F-fluorodeoxyglucose PET/CT scan showed an abnormal collection in the enlarged lymph nodes. The patient subsequently developed hoarseness with dyspnea and attended our department. Blood test results showed high levels of lactate dehydrogenase (547U/L) and soluble interleukin‐2 receptor (34200 IU/L) and were positive for anti-human T-cell leukemia virus type1 (HTLV‐1) antibody. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells positive for CD3, CD4, and CD25 and negative for CD7. Monoclonal integration of HTLV‐1 proviral DNA was detected in the lymph node. A diagnosis of adult T-cell leukemia/lymphoma (ATLL), lymphoma type was made. The pain involving multiple joints was attributed to HTLV‐1associated arthropathy. Immunosuppressive therapy for HTLV‐1 carrier status may have played a role in the development of ATLL.","ja":"A 64-year-old woman presented with lower leg edema, fever, and bilateral joint pain, involving the wrists, fingers, and knees, in April 201X. Serological test results were negative for rheumatoid factor, antinuclear antibody, and anti-cyclic citrullinated peptide antibody. A diagnosis of remitting seronegative symmetrical synovitis with pitting edema syndrome, a type of seronegative rheumatoid arthritis, was made and prednisolone was administered. The joint pain was refractory to prednisolone therapy. In February, 201X+2, the patient presented with right cervical lymphadenopathy. The CT scan revealed swelling of the cervical, axillary, and inguinal lymph nodes bilaterally and rapidly enlarged. In April, 18F-fluorodeoxyglucose PET/CT scan showed an abnormal collection in the enlarged lymph nodes. The patient subsequently developed hoarseness with dyspnea and attended our department. Blood test results showed high levels of lactate dehydrogenase (547U/L) and soluble interleukin‐2 receptor (34200 IU/L) and were positive for anti-human T-cell leukemia virus type1 (HTLV‐1) antibody. Biopsy of the right cervical lymph node showed proliferation of abnormal lymphoid cells positive for CD3, CD4, and CD25 and negative for CD7. Monoclonal integration of HTLV‐1 proviral DNA was detected in the lymph node. A diagnosis of adult T-cell leukemia/lymphoma (ATLL), lymphoma type was made. The pain involving multiple joints was attributed to HTLV‐1associated arthropathy. Immunosuppressive therapy for HTLV‐1 carrier status may have played a role in the development of ATLL."},"publication_date":"2017-12-25","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.73","number":"No.5,6","starting_page":"301","ending_page":"308","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113059","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29535808","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85041952629&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339730","label":"url"}],"paper_title":{"en":"Effective impairment of myeloma cells and their progenitors by hyperthermia.","ja":"Effective impairment of myeloma cells and their progenitors by hyperthermia."},"authors":{"en":[{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Oda Asuka"},{"name":"Tenshin Hirofumi"},{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Maeda Yusaku"},{"name":"Oura Masahiro"},{"name":"Takahashi Mamiko"},{"name":"Iwasa Masami"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Kurahashi Kiyoe"},{"name":"Yoshida Sumiko"},{"name":"Kagawa Kumiko"},{"name":"Endo Itsuro"},{"name":"Kenichi Aihara"},{"name":"Ikuo Mariko"},{"name":"Itou Kouji"},{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Abe Masahiro"}],"ja":[{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"Oda Asuka"},{"name":"天眞 寛文"},{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Maeda Yusaku"},{"name":"大浦 雅博"},{"name":"Takahashi Mamiko"},{"name":"Iwasa Masami"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"倉橋 清衛"},{"name":"吉田 守美子"},{"name":"賀川 久美子"},{"name":"遠藤 逸朗"},{"name":"Kenichi Aihara"},{"name":"幾尾 真理子"},{"name":"伊藤 孝司"},{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"安倍 正博"}]},"description":{"en":"Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated \"side population\" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs.","ja":"Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated \"side population\" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs."},"publication_date":"2017-11-15","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"Vol.9","number":"No.12","starting_page":"10307","ending_page":"10316","languages":["eng"],"referee":true,"identifiers":{"doi":["10.18632/oncotarget.23121"],"issn":["1949-2553"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/111724","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29296860","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=336276","label":"url"}],"paper_title":{"en":"TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.","ja":"TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects."},"authors":{"en":[{"name":"Tenshin Hirofumi"},{"name":"Teramachi Jumpei"},{"name":"Oda Asuka"},{"name":"Amachi Ryota"},{"name":"Hiasa Masahiro"},{"name":"Bat-Erdene Ariunzaya"},{"name":"Watanabe Keiichiro"},{"name":"Iwasa Masami"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Sogabe Kimiko"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kurahashi Kiyoe"},{"name":"Yoshida Sumiko"},{"name":"Aihara Kenichi"},{"name":"Endo Itsuro"},{"name":"Tanaka Eiji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"天眞 寛文"},{"name":"寺町 順平"},{"name":"Oda Asuka"},{"name":"天知 良太"},{"name":"日浅 雅博"},{"name":"Ariunzaya Bat-Erdene"},{"name":"渡邉 佳一郎"},{"name":"岩佐 昌美"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"曽我部 公子"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"倉橋 清衛"},{"name":"吉田 守美子"},{"name":"Aihara Kenichi"},{"name":"遠藤 逸朗"},{"name":"田中 栄二"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-B ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor -activated kinase-1 (TAK1), and thus activated NF-B signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-B activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-B activation, and that TAK1 inhibition subverts TRAIL-mediated NF-B activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL.","ja":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, thereby forming a vicious cycle between MM tumor expansion and bone destruction. However, the effects of TRAIL on MM-enhanced osteoclastogenesis remain largely unknown. Here, we show that TRAIL induced apoptosis in MM cells, but not in osteoclasts (OCs), and that it rather facilitated receptor activator of NF-B ligand-induced osteoclastogenesis along with upregulation of cellular FLICE inhibitory protein (c-FLIP). TRAIL did not induce death-inducing signaling complex formation in OCs, but formed secondary complex (complex II) with the phosphorylation of transforming growth factor -activated kinase-1 (TAK1), and thus activated NF-B signaling. c-FLIP knockdown abolished complex II formation, thus permitting TRAIL induction of OC cell death. The TAK1 inhibitor LLZ1640-2 abrogated the TRAIL-induced c-FLIP upregulation and NF-B activation, and triggered TRAIL-induced caspase-8 activation and cell death in OCs. Interestingly, the TRAIL-induced caspase-8 activation caused enzymatic degradation of the transcription factor Sp1 to noticeably reduce c-FLIP expression, which further sensitized OCs to TRAIL-induced apoptosis. Furthermore, the TAK1 inhibition induced antiosteoclastogenic activity by TRAIL even in cocultures with MM cells while potentiating TRAIL's anti-MM effects. These results demonstrated that osteoclastic lineage cells use TRAIL for their differentiation and activation through tilting caspase-8-dependent apoptosis toward NF-B activation, and that TAK1 inhibition subverts TRAIL-mediated NF-B activation to resume TRAIL-induced apoptosis in OCs while further enhancing MM cell death in combination with TRAIL."},"publication_date":"2017-10-26","publication_name":{"en":"Blood Advances","ja":"Blood Advances"},"volume":"Vol.1","number":"No.24","starting_page":"2124","ending_page":"2137","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1182/bloodadvances.2017008813"],"issn":["2473-9529"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28694074","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=328824","label":"url"}],"paper_title":{"en":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","ja":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis"},"authors":{"en":[{"name":"Kohei Muto"},{"name":"Matsui Naoko"},{"name":"Yuki Unai"},{"name":"Waka Sakai"},{"name":"Shotaro Haji"},{"name":"Kengo Udaka"},{"name":"Miki Hirokazu"},{"name":"Furukawa Takahiro"},{"name":"Abe Masahiro"},{"name":"Kaji Ryuji"}],"ja":[{"name":"Kohei Muto"},{"name":"松井 尚子"},{"name":"Yuki Unai"},{"name":"酒井 和香"},{"name":"土師 正太郎"},{"name":"Kengo Udaka"},{"name":"三木 浩和"},{"name":"古川 貴大"},{"name":"安倍 正博"},{"name":"梶 龍兒"}]},"description":{"en":"The immunologic effects of rituximab (RTX) in myasthenia gravis (MG) remain to be explored. We aimed to clarify immunologic reactions and their association with response to RTX in MG. Regulatory T cell and B cell profiles of MG patients were monitored. Two patients presenting with generalized MG with anti-acetylcholine receptor antibodies were treated with RTX. The treatment led to sustained clinical improvement, discontinuation of intravenous immunoglobulin or plasma exchange, and reduction of prednisolone and other drugs. One patient was in remission for more than one year, whereas the other patient exhibited deterioration of symptoms within one year. Disease activity was associated with the repopulation of IgDCD27 and IgDCD27 memory B cells. Clinicians should be aware of the possibility that MG ranges in the duration of B cell depletion and additional RTX should be prescribed upon resurgence of memory B cells.","ja":"The immunologic effects of rituximab (RTX) in myasthenia gravis (MG) remain to be explored. We aimed to clarify immunologic reactions and their association with response to RTX in MG. Regulatory T cell and B cell profiles of MG patients were monitored. Two patients presenting with generalized MG with anti-acetylcholine receptor antibodies were treated with RTX. The treatment led to sustained clinical improvement, discontinuation of intravenous immunoglobulin or plasma exchange, and reduction of prednisolone and other drugs. One patient was in remission for more than one year, whereas the other patient exhibited deterioration of symptoms within one year. Disease activity was associated with the repopulation of IgDCD27 and IgDCD27 memory B cells. Clinicians should be aware of the possibility that MG ranges in the duration of B cell depletion and additional RTX should be prescribed upon resurgence of memory B cells."},"publication_date":"2017-06-21","publication_name":{"en":"Neuromuscular Disorders","ja":"Neuromuscular Disorders"},"volume":"Vol.27","number":"No.16","starting_page":"918","ending_page":"922","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.nmd.2017.06.012"],"issn":["1873-2364"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109988","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27738323","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=326832","label":"url"}],"paper_title":{"en":"Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.","ja":"Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors."},"authors":{"en":[{"name":"Bat-Erdene Ariunzaya"},{"name":"Miki Hirokazu"},{"name":"Oda Asuko"},{"name":"Nakamura Shingen"},{"name":"Teramachi Jumpei"},{"name":"Amachi Ryota"},{"name":"Tenshin Hirofumi"},{"name":"Hiasa Masahiro"},{"name":"Iwasa Masami"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Sogabe Kimiko"},{"name":"Kagawa Kumiko"},{"name":"Yoshida Sumiko"},{"name":"Endo Itsuro"},{"name":"Aihara Ken-ichi"},{"name":"Abe Masahiro"}],"ja":[{"name":"Bat-Erdene Ariunzaya"},{"name":"三木 浩和"},{"name":"Oda Asuko"},{"name":"中村 信元"},{"name":"寺町 順平"},{"name":"天知 良太"},{"name":"天眞 寛文"},{"name":"日浅 雅博"},{"name":"Iwasa Masami"},{"name":"原田 武志"},{"name":"藤井 志朗"},{"name":"Sogabe Kimiko"},{"name":"賀川 久美子"},{"name":"吉田 守美子"},{"name":"遠藤 逸朗"},{"name":"粟飯原 賢一"},{"name":"安倍 正博"}]},"description":{"en":"Panobinostat, a pan-deacetylase inhibitor, synergistically elicits cytotoxic activity against myeloma (MM) cells in combination with the proteasome inhibitor bortezomib. Because precise mechanisms for panobinostat's anti-MM action still remain elusive, we aimed to clarify the mechanisms of anti-MM effects of panobinostat and its synergism with proteasome inhibitors. Although the transcription factor Sp1 was overexpressed in MM cells, the Sp1 inhibitor terameprocol induced MM cell death in parallel with reduction of IRF4 and cMyc. Panobinostat induced activation of caspase-8, which was inversely correlated with reduction of Sp1 protein levels in MM cells. The panobinostat-mediated effects were further potentiated to effectively induce MM cell death in combination with bortezomib or carfilzomib even at suboptimal concentrations as a single agent. Addition of the caspase-8 inhibitor z-IETD-FMK abolished the Sp1 reduction not only by panobinostat alone but also by its combination with bortezomib, suggesting caspase-8-mediated Sp1 degradation. The synergistic Sp1 reduction markedly suppressed Sp1-driven prosurvival factors, IRF4 and cMyc. Besides, the combinatory treatment reduced HDAC1, another Sp1 target, in MM cells, which may potentiate HDAC inhibition. Collectively, caspase-8-mediated post-translational Sp1 degradation appears to be among major mechanisms for synergistic anti-MM effects of panobinostat and proteasome inhibitors in combination.","ja":"Panobinostat, a pan-deacetylase inhibitor, synergistically elicits cytotoxic activity against myeloma (MM) cells in combination with the proteasome inhibitor bortezomib. Because precise mechanisms for panobinostat's anti-MM action still remain elusive, we aimed to clarify the mechanisms of anti-MM effects of panobinostat and its synergism with proteasome inhibitors. Although the transcription factor Sp1 was overexpressed in MM cells, the Sp1 inhibitor terameprocol induced MM cell death in parallel with reduction of IRF4 and cMyc. Panobinostat induced activation of caspase-8, which was inversely correlated with reduction of Sp1 protein levels in MM cells. The panobinostat-mediated effects were further potentiated to effectively induce MM cell death in combination with bortezomib or carfilzomib even at suboptimal concentrations as a single agent. Addition of the caspase-8 inhibitor z-IETD-FMK abolished the Sp1 reduction not only by panobinostat alone but also by its combination with bortezomib, suggesting caspase-8-mediated Sp1 degradation. The synergistic Sp1 reduction markedly suppressed Sp1-driven prosurvival factors, IRF4 and cMyc. Besides, the combinatory treatment reduced HDAC1, another Sp1 target, in MM cells, which may potentiate HDAC inhibition. Collectively, caspase-8-mediated post-translational Sp1 degradation appears to be among major mechanisms for synergistic anti-MM effects of panobinostat and proteasome inhibitors in combination."},"publication_date":"2016-11-29","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"Vol.7","number":"No.48","starting_page":"79064","ending_page":"79075","languages":["eng"],"referee":true,"identifiers":{"doi":["10.18632/oncotarget.12594"],"issn":["1949-2553"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113048","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27626482","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=323181","label":"url"}],"paper_title":{"en":"A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.","ja":"A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration."},"authors":{"en":[{"name":"Amachi Ryota"},{"name":"Hiasa Masahiro"},{"name":"Teramachi Jumpei"},{"name":"Harada Takeshi"},{"name":"Oda Asuka"},{"name":"Nakamura Shingen"},{"name":"Hanson Derek"},{"name":"Watanabe Keiichiro"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Iwasa Masami"},{"name":"Endo Itsuro"},{"name":"Kondo Takeshi"},{"name":"Yoshida Sumiko"},{"name":"Aihara Ken-ichi"},{"name":"Kurahashi Kiyoe"},{"name":"Kuroda Yoshiaki"},{"name":"Horikawa Hideaki"},{"name":"Tanaka Eiji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"天知 良太"},{"name":"日浅 雅博"},{"name":"寺町 順平"},{"name":"原田 武志"},{"name":"小田 明日香"},{"name":"中村 信元"},{"name":"Derek James Hanson"},{"name":"渡邉 佳一郎"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"岩佐 昌美"},{"name":"遠藤 逸朗"},{"name":"近藤 剛史"},{"name":"吉田 守美子"},{"name":"粟飯原 賢一"},{"name":"倉橋 清衛"},{"name":"黒田 芳明"},{"name":"堀川 秀昌"},{"name":"田中 栄二"},{"name":"安倍 正博"},{"name":"松本 俊夫"}]},"description":{"en":"Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells and its role in MM cell response to acidic conditions. Acidic conditions activated the PI3K-Akt signaling in MM cells while upregulating the pH sensor transient receptor potential cation channel subfamily V member 1 (TRPV1) in a manner inhibitable by PI3K inhibition. The acid-activated PI3K-Akt signaling facilitated the nuclear localization of the transcription factor Sp1 to trigger the expression of its target genes, including TRPV1 and HDAC1. Consistently, histone deacetylation was enhanced in MM cells in acidic conditions, while repressing a wide variety of genes, including DR4. Indeed, acidic conditions deacetylated histone H3K9 in a DR4 gene promoter and curtailed DR4 expression in MM cells. However, inhibition of HDAC as well as either Sp1 or PI3K was able to restore DR4 expression in MM cells suppressed in acidic conditions. These results collectively demonstrate that acid activates the TRPV1-PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, and suggest that a positive feedback loop between acid sensing and the PI3K-Akt signaling is formed in MM cells, leading to MM cell response to acidic bone lesions.","ja":"Myeloma (MM) cells and osteoclasts are mutually interacted to enhance MM growth while creating acidic bone lesions. Here, we explored acid sensing of MM cells and its role in MM cell response to acidic conditions. Acidic conditions activated the PI3K-Akt signaling in MM cells while upregulating the pH sensor transient receptor potential cation channel subfamily V member 1 (TRPV1) in a manner inhibitable by PI3K inhibition. The acid-activated PI3K-Akt signaling facilitated the nuclear localization of the transcription factor Sp1 to trigger the expression of its target genes, including TRPV1 and HDAC1. Consistently, histone deacetylation was enhanced in MM cells in acidic conditions, while repressing a wide variety of genes, including DR4. Indeed, acidic conditions deacetylated histone H3K9 in a DR4 gene promoter and curtailed DR4 expression in MM cells. However, inhibition of HDAC as well as either Sp1 or PI3K was able to restore DR4 expression in MM cells suppressed in acidic conditions. These results collectively demonstrate that acid activates the TRPV1-PI3K-Akt-Sp1 signaling in MM cells while inducing HDAC-mediated gene repression, and suggest that a positive feedback loop between acid sensing and the PI3K-Akt signaling is formed in MM cells, leading to MM cell response to acidic bone lesions."},"publication_date":"2016-10-25","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"Vol.7","number":"No.43","starting_page":"70447","ending_page":"70461","languages":["eng"],"referee":true,"identifiers":{"doi":["10.18632/oncotarget.11927"],"issn":["1949-2553"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27698446","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=326829","label":"url"}],"paper_title":{"en":"Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.","ja":"Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid."},"authors":{"en":[{"name":"Harada Takeshi"},{"name":"Miki Hirokazu"},{"name":"Cui Q"},{"name":"Oda A"},{"name":"Amachi Ryota"},{"name":"Teramachi Jumpei"},{"name":"Bat-Erdene A"},{"name":"Sogabe K"},{"name":"Iwasa M"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Kagawa Kumiko"},{"name":"Yoshida Sumiko"},{"name":"Endo I"},{"name":"Aihara Ken-ichi"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"原田 武志"},{"name":"三木 浩和"},{"name":"Cui Q"},{"name":"Oda A"},{"name":"天知 良太"},{"name":"寺町 順平"},{"name":"Bat-Erdene A"},{"name":"Sogabe K"},{"name":"Iwasa M"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"賀川 久美子"},{"name":"吉田 守美子"},{"name":"Endo I"},{"name":"粟飯原 賢一"},{"name":"尾崎 修治"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"publication_date":"2016-10-04","publication_name":{"en":"Leukemia","ja":"Leukemia"},"volume":"Vol.31","number":"No.1","starting_page":"258","ending_page":"262","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/leu.2016.273"],"issn":["1476-5551"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109501","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26384349","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84946086135&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=310845","label":"url"}],"paper_title":{"en":"Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.","ja":"Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation."},"authors":{"en":[{"name":"Hanson Derek James"},{"name":"Nakamura Shingen"},{"name":"Amachi Ryota"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Tsuji Daisuke"},{"name":"Itoh Kohji"},{"name":"Harada Takeshi"},{"name":"Horikawa Kazuki"},{"name":"Teramachi Jumpei"},{"name":"Miki Hirokazu"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"Hanson Derek James"},{"name":"中村 信元"},{"name":"天知 良太"},{"name":"日浅 雅博"},{"name":"Oda Asuka"},{"name":"辻 大輔"},{"name":"Itoh Kohji"},{"name":"Harada Takeshi"},{"name":"堀川 一樹"},{"name":"寺町 順平"},{"name":"三木 浩和"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Cancer cells robustly expel lactate produced through enhanced glycolysis via monocarboxylate transporters (MCTs) and maintain alkaline intracellular pH. To develop a novel therapeutic strategy against multiple myeloma (MM), which still remains incurable, we explored the impact of perturbing a metabolism via inhibiting MCTs. All MM cells tested constitutively expressed MCT1 and MCT4, and most expressed MCT2. Lactate export was substantially suppressed to induce death along with lowering intracellular pH in MM cells by blockade of all three MCT molecules with -cyano-4-hydroxy cinnamate (CHC) or the MCT1 and MCT2 inhibitor AR-C155858 in combination with MCT4 knockdown, although only partially by knockdown of each MCT. CHC lowered intracellular pH and severely curtailed lactate secretion even when combined with metformin, which further lowered intracellular pH and enhanced cytotoxicity. Interestingly, an ambient acidic pH markedly enhanced CHC-mediated cytotoxicity, suggesting preferential targeting of MM cells in acidic MM bone lesions. Furthermore, treatment with CHC suppressed hexokinase II expression and ATP production to reduce side populations and colony formation. Finally, CHC caused downregulation of homing receptor CXCR4 and abrogated SDF-1-induced migration. Targeting tumor metabolism by MCT blockade therefore may become an effective therapeutic option for drug-resistant MM cells with elevated glycolysis.","ja":"Cancer cells robustly expel lactate produced through enhanced glycolysis via monocarboxylate transporters (MCTs) and maintain alkaline intracellular pH. To develop a novel therapeutic strategy against multiple myeloma (MM), which still remains incurable, we explored the impact of perturbing a metabolism via inhibiting MCTs. All MM cells tested constitutively expressed MCT1 and MCT4, and most expressed MCT2. Lactate export was substantially suppressed to induce death along with lowering intracellular pH in MM cells by blockade of all three MCT molecules with -cyano-4-hydroxy cinnamate (CHC) or the MCT1 and MCT2 inhibitor AR-C155858 in combination with MCT4 knockdown, although only partially by knockdown of each MCT. CHC lowered intracellular pH and severely curtailed lactate secretion even when combined with metformin, which further lowered intracellular pH and enhanced cytotoxicity. Interestingly, an ambient acidic pH markedly enhanced CHC-mediated cytotoxicity, suggesting preferential targeting of MM cells in acidic MM bone lesions. Furthermore, treatment with CHC suppressed hexokinase II expression and ATP production to reduce side populations and colony formation. Finally, CHC caused downregulation of homing receptor CXCR4 and abrogated SDF-1-induced migration. Targeting tumor metabolism by MCT blockade therefore may become an effective therapeutic option for drug-resistant MM cells with elevated glycolysis."},"publication_date":"2015-10-20","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"Vol.6","number":"No.32","starting_page":"33568","ending_page":"33586","languages":["eng"],"referee":true,"identifiers":{"doi":["10.18632/oncotarget.5598"],"issn":["1949-2553"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=318276","label":"url"}],"paper_title":{"en":"Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions","ja":"Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions"},"authors":{"en":[{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Oda Asuka"},{"name":"Amachi Ryota"},{"name":"Teramachi Jumpei"},{"name":"Sogabe Kimiko"},{"name":"Fujino Hikaru"},{"name":"Maruhashi Tomoko"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Abe Masahiro"}],"ja":[{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"Oda Asuka"},{"name":"Amachi Ryota"},{"name":"寺町 順平"},{"name":"曽我部 公子"},{"name":"Fujino Hikaru"},{"name":"Maruhashi Tomoko"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"安倍 正博"}]},"publication_date":"2015-10","publication_name":{"en":"International Journal of Myeloma","ja":"International Journal of Myeloma"},"volume":"Vol.6","number":"No.1","starting_page":"7","ending_page":"11","languages":["eng"],"referee":true,"identifiers":{"issn":["2187-3143"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2017035595","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390292815284471040/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=303535","label":"url"}],"paper_title":{"en":"Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death","ja":"Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death"},"authors":{"en":[{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Oda A"},{"name":"Amachi R"},{"name":"Watanabe Keiichiro"},{"name":"Hanson D"},{"name":"Teramachi Jumpei"},{"name":"Hiasa Masahiro"},{"name":"Yagi H"},{"name":"Sogabe K"},{"name":"Takahashi M"},{"name":"Maruhashi T"},{"name":"Udaka K"},{"name":"Harada T"},{"name":"Fujii Shiroh"},{"name":"Nakano A"},{"name":"Kagawa Kumiko"},{"name":"Ri M"},{"name":"Iida S"},{"name":"Ozaki Shuji"},{"name":"Matsumoto T"},{"name":"Abe Masahiro"}],"ja":[{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"Oda A"},{"name":"Amachi R"},{"name":"渡邉 佳一郎"},{"name":"Hanson D"},{"name":"寺町 順平"},{"name":"日浅 雅博"},{"name":"Yagi H"},{"name":"Sogabe K"},{"name":"Takahashi M"},{"name":"Maruhashi T"},{"name":"Udaka K"},{"name":"Harada T"},{"name":"藤井 志朗"},{"name":"Nakano A"},{"name":"賀川 久美子"},{"name":"Ri M"},{"name":"Iida S"},{"name":"尾崎 修治"},{"name":"Matsumoto T"},{"name":"安倍 正博"}]},"description":{"en":"
TNF-related apoptosis-including ligand/Apo2 (TRAIL)-mediated immunotherapy is an attractive anti-tumor modality with high tumor specificity. In order to improve its therapeutic efficacy, we further need to implement a novel maneuver for sensitization of malignant cells to TRAIL. Bortezomib (BTZ), a novel anti-myeloma (MM) agent, potently induces endoplasmic reticulum (ER) stress to cause apoptosis. Here, we explored the roles of BTZ in the cytotoxicity of anti-TRAIL receptor agonistic antibodies against MM cells with special reference to ER stress. BTZ enhanced the expression of death receptor 5 (DR5) but not DR4 in MM cells at surface protein as well as mRNA levels. However, the DR5 expression was not affected by BTZ without ER stress induction in MM cells with a point mutation in a BTZ-binding proteasome β5 subunit. Tunicamycin, an ER stress inducer, was able to enhance the DR5 expression even in the BTZ-resistant MM cells, suggesting the role of ER stress in up-regulation of DR5 expression. Interestingly, BTZ facilitated extrinsic caspase-mediated apoptosis by anti-DR5 agonistic antibody in MM cells along with reducing c-FLICE-like interleukin protein, a caspase 8 inhibitor. These results suggest that BTZ enhances DR5 expression and its downstream apoptotic signaling through ER stress to sensitize MM cells to TRAIL-mediated immunotherapy.
","ja":"TNF-related apoptosis-including ligand/Apo2 (TRAIL)-mediated immunotherapy is an attractive anti-tumor modality with high tumor specificity. In order to improve its therapeutic efficacy, we further need to implement a novel maneuver for sensitization of malignant cells to TRAIL. Bortezomib (BTZ), a novel anti-myeloma (MM) agent, potently induces endoplasmic reticulum (ER) stress to cause apoptosis. Here, we explored the roles of BTZ in the cytotoxicity of anti-TRAIL receptor agonistic antibodies against MM cells with special reference to ER stress. BTZ enhanced the expression of death receptor 5 (DR5) but not DR4 in MM cells at surface protein as well as mRNA levels. However, the DR5 expression was not affected by BTZ without ER stress induction in MM cells with a point mutation in a BTZ-binding proteasome β5 subunit. Tunicamycin, an ER stress inducer, was able to enhance the DR5 expression even in the BTZ-resistant MM cells, suggesting the role of ER stress in up-regulation of DR5 expression. Interestingly, BTZ facilitated extrinsic caspase-mediated apoptosis by anti-DR5 agonistic antibody in MM cells along with reducing c-FLICE-like interleukin protein, a caspase 8 inhibitor. These results suggest that BTZ enhances DR5 expression and its downstream apoptotic signaling through ER stress to sensitize MM cells to TRAIL-mediated immunotherapy.
"},"publication_date":"2015-01","publication_name":{"en":"International Journal of Myeloma","ja":"International Journal of Myeloma"},"volume":"Vol.5","number":"No.1","starting_page":"1","ending_page":"7","languages":["eng"],"referee":true,"identifiers":{"doi":["10.57352/ijm.5.1_1"],"issn":["2187-3143"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24955144","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84902517614&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=286935","label":"url"}],"paper_title":{"en":"Magnetically Responsive Smart Nanoparticles for Cancer Treatment with a Combination of Magnetic Hyperthermia and Remote-Control Drug Release","ja":"Magnetically Responsive Smart Nanoparticles for Cancer Treatment with a Combination of Magnetic Hyperthermia and Remote-Control Drug Release"},"authors":{"en":[{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"},{"name":"Wataru Sakamoto"},{"name":"Toshinobu Yogo"},{"name":"Ishimura Kazunori"}],"ja":[{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"},{"name":"松本 俊夫"},{"name":"Wataru Sakamoto"},{"name":"Toshinobu Yogo"},{"name":"石村 和敬"}]},"description":{"en":"We report the synthesis of smart nanoparticles (NPs) that generate heat in response to an alternating current magnetic field (ACMF) and that sequentially release an anticancer drug (doxorubicin, DOX). We further study the in vivo therapeutic efficacy of the combination of magnetic hyperthermia (MHT) and chemotherapy using the smart NPs for the treatment of multiple myeloma. The smart NPs are composed of a polymer with a glass-transition temperature (T g) of 44°C, which contains clustered Fe3O4 NPs and DOX. The clustered Fe3O4 NPs produce heat when the ACMF is applied and rise above 44°C, which softens the polymer phase and leads to the release of DOX. The combination of MHT and chemotherapy using the smart NPs destroys cancer cells in the entire tumor and achieves a complete cure in one treatment without the recurrence of malignancy. Furthermore, the smart NPs have no significant toxicity.","ja":"We report the synthesis of smart nanoparticles (NPs) that generate heat in response to an alternating current magnetic field (ACMF) and that sequentially release an anticancer drug (doxorubicin, DOX). We further study the in vivo therapeutic efficacy of the combination of magnetic hyperthermia (MHT) and chemotherapy using the smart NPs for the treatment of multiple myeloma. The smart NPs are composed of a polymer with a glass-transition temperature (T g) of 44°C, which contains clustered Fe3O4 NPs and DOX. The clustered Fe3O4 NPs produce heat when the ACMF is applied and rise above 44°C, which softens the polymer phase and leads to the release of DOX. The combination of MHT and chemotherapy using the smart NPs destroys cancer cells in the entire tumor and achieves a complete cure in one treatment without the recurrence of malignancy. Furthermore, the smart NPs have no significant toxicity."},"publication_date":"2014-06-07","publication_name":{"en":"Theranostics","ja":"Theranostics"},"volume":"Vol.4","number":"No.8","starting_page":"834","ending_page":"844","languages":["eng"],"referee":true,"identifiers":{"doi":["10.7150/thno.9199"],"issn":["1838-7640"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/109757","label":"url"},{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/109757","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1050001337464993408/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=303542","label":"url"}],"paper_title":{"en":"Successful treatment of refractory severe aplastic anemia with bone marrow transplantation from a genetically identical twin","ja":"同系骨髄移植が著効した最重症再生不良性貧血の1例"},"authors":{"en":[{"name":"Kagawa Kumiko"},{"name":"Nakamura Shingen"},{"name":"八木 ひかる"},{"name":"Sogabe Kimiko"},{"name":"髙橋 真美子"},{"name":"丸橋 朋子"},{"name":"宇髙 憲吾"},{"name":"Fujii Shiroh"},{"name":"Miki Hirokazu"},{"name":"Abe Masahiro"}],"ja":[{"name":"賀川 久美子"},{"name":"中村 信元"},{"name":"八木 ひかる"},{"name":"曽我部 公子"},{"name":"髙橋 真美子"},{"name":"丸橋 朋子"},{"name":"宇髙 憲吾"},{"name":"藤井 志朗"},{"name":"三木 浩和"},{"name":"安倍 正博"}]},"description":{"en":"Aplastic anemia is a bone marrow failure caused by severely curtailed hematopoietic stem cells (HSCs) and dysregulation of ambient immune cells. Immumo-suppressive conditioning followed by allogeneic HSC transplantation is currently a mainstay in treatment for patients at a younger age or those refractory to conventional immunosuppressive remedies. Syngeneic HSC transplantation appears to be promising, but has been very rarely performed ; therefore, its impact on a long-term outcome as well as the best preparative measures for HSC engraftment and immune amelioration are still largely unknown. Here, we reported a successful and beneficial syngeneic HSC transplantation for a refractory case with very severe aplastic anemia. A 30-year-old female presented high fever after tooth extraction, and was diagnosed with very severe aplastic anemia. Cyclosporine and anti-thymocyte globulin were initiated, but showed no hematological effects. After obtaining an informed consent, she underwent bone marrow transplantation from a genetically identical twin following an non-myeloablative conditioning regimen consisted of cyclophosphamide (750mg/m2, 4 days), fludarabine phosphate (25mg/m2, 4 days). Cyclosporine was given for acute GvHD prophylaxis. Her neutrophils recovered over 500/μl on 12 days after the transplantation, and her blood counts have been maintained in a normal range over 7 years thereafter. Although a fate of HSCs from a genetically identical twin and an immune response of ambient cells in the bone marrow in recipients remains largely unknown, from the present case and previously reported cases, we dare to recommend immunoablative conditioning and acute GvHD prophylaxis in syngeneic HSC transplantation for a refractory case with aplastic anemia for better engraftment and sustained onward recovery of hematopoiesis.","ja":"Aplastic anemia is a bone marrow failure caused by severely curtailed hematopoietic stem cells (HSCs) and dysregulation of ambient immune cells. Immumo-suppressive conditioning followed by allogeneic HSC transplantation is currently a mainstay in treatment for patients at a younger age or those refractory to conventional immunosuppressive remedies. Syngeneic HSC transplantation appears to be promising, but has been very rarely performed ; therefore, its impact on a long-term outcome as well as the best preparative measures for HSC engraftment and immune amelioration are still largely unknown. Here, we reported a successful and beneficial syngeneic HSC transplantation for a refractory case with very severe aplastic anemia. A 30-year-old female presented high fever after tooth extraction, and was diagnosed with very severe aplastic anemia. Cyclosporine and anti-thymocyte globulin were initiated, but showed no hematological effects. After obtaining an informed consent, she underwent bone marrow transplantation from a genetically identical twin following an non-myeloablative conditioning regimen consisted of cyclophosphamide (750mg/m2, 4 days), fludarabine phosphate (25mg/m2, 4 days). Cyclosporine was given for acute GvHD prophylaxis. Her neutrophils recovered over 500/μl on 12 days after the transplantation, and her blood counts have been maintained in a normal range over 7 years thereafter. Although a fate of HSCs from a genetically identical twin and an immune response of ambient cells in the bone marrow in recipients remains largely unknown, from the present case and previously reported cases, we dare to recommend immunoablative conditioning and acute GvHD prophylaxis in syngeneic HSC transplantation for a refractory case with aplastic anemia for better engraftment and sustained onward recovery of hematopoiesis."},"publication_date":"2014-06","publication_name":{"en":"Shikoku Acta Medica","ja":"四国医学雑誌"},"volume":"Vol.70","number":"No.3,4","starting_page":"77","ending_page":"80","languages":["jpn"],"referee":true,"identifiers":{"issn":["0037-3699"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24787487","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=283755","label":"url"}],"paper_title":{"en":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.","ja":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma."},"authors":{"en":[{"name":"Hiasa Masahiro"},{"name":"Teramachi Jumpei"},{"name":"Oda A"},{"name":"Amachi Ryota"},{"name":"Harada T"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Fujii Shiroh"},{"name":"Kagawa Kumiko"},{"name":"Watanabe Keiichiro"},{"name":"Endo Itsuro"},{"name":"Kuroda Y"},{"name":"Yoneda T"},{"name":"Tsuji Daisuke"},{"name":"Nakao Michiyasu"},{"name":"Tanaka Eiji"},{"name":"Hamada Kenichi"},{"name":"Sano Shigeki"},{"name":"Itou Kouji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"日浅 雅博"},{"name":"寺町 順平"},{"name":"Oda A"},{"name":"天知 良太"},{"name":"Harada T"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"藤井 志朗"},{"name":"賀川 久美子"},{"name":"渡邉 佳一郎"},{"name":"遠藤 逸朗"},{"name":"Kuroda Y"},{"name":"Yoneda T"},{"name":"辻 大輔"},{"name":"中尾 允泰"},{"name":"田中 栄二"},{"name":"浜田 賢一"},{"name":"佐野 茂樹"},{"name":"伊藤 孝司"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Pim-2 kinase is overexpressed in multiple myeloma (MM) cells to enhance their growth and survival, and regarded as a novel therapeutic target in MM. However, the impact of Pim-2 inhibition on bone disease in MM remains unknown. We demonstrated here that Pim-2 expression was also upregulated in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells in the presence of cytokines known as the inhibitors of osteoblastogenesis in MM, including interleukin-3 (IL-3), IL-7, tumor necrosis factor-, transforming growth factor- (TGF-) and activin A, as well as MM cell conditioned media. The enforced expression of Pim-2 abrogated in vitro osteoblastogenesis by BMP-2, which suggested Pim-2 as a negative regulator for osteoblastogenesis. Treatment with Pim-2 short-interference RNA as well as the Pim inhibitor SMI-16a successfully restored osteoblastogenesis suppressed by all the above inhibitory factors and MM cells. The SMI-16a treatment potentiated BMP-2-mediated anabolic signaling while suppressing TGF- signaling. Furthermore, treatment with the newly synthesized thiazolidine-2,4-dione congener, 12a-OH, as well as its prototypic SMI-16a effectively prevented bone destruction while suppressing MM tumor growth in MM animal models. Thus, Pim-2 may have a pivotal role in tumor progression and bone loss in MM, and Pim-2 inhibition may become an important therapeutic strategy to target the MM cell-bone marrow interaction.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.147.","ja":"Pim-2 kinase is overexpressed in multiple myeloma (MM) cells to enhance their growth and survival, and regarded as a novel therapeutic target in MM. However, the impact of Pim-2 inhibition on bone disease in MM remains unknown. We demonstrated here that Pim-2 expression was also upregulated in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells in the presence of cytokines known as the inhibitors of osteoblastogenesis in MM, including interleukin-3 (IL-3), IL-7, tumor necrosis factor-, transforming growth factor- (TGF-) and activin A, as well as MM cell conditioned media. The enforced expression of Pim-2 abrogated in vitro osteoblastogenesis by BMP-2, which suggested Pim-2 as a negative regulator for osteoblastogenesis. Treatment with Pim-2 short-interference RNA as well as the Pim inhibitor SMI-16a successfully restored osteoblastogenesis suppressed by all the above inhibitory factors and MM cells. The SMI-16a treatment potentiated BMP-2-mediated anabolic signaling while suppressing TGF- signaling. Furthermore, treatment with the newly synthesized thiazolidine-2,4-dione congener, 12a-OH, as well as its prototypic SMI-16a effectively prevented bone destruction while suppressing MM tumor growth in MM animal models. Thus, Pim-2 may have a pivotal role in tumor progression and bone loss in MM, and Pim-2 inhibition may become an important therapeutic strategy to target the MM cell-bone marrow interaction.Leukemia advance online publication, 30 May 2014; doi:10.1038/leu.2014.147."},"publication_date":"2014-05-02","publication_name":{"en":"Leukemia","ja":"Leukemia"},"languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/leu.2014.147"],"issn":["1476-5551"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84892950115&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=286934","label":"url"}],"paper_title":{"en":"Photostable Iodinated Silica/Porphyrin Hybrid Nanoparticles with Heavy-Atom Effect for Wide-Field Photodynamic/Photothermal Therapy Using Single Light Source","ja":"Photostable Iodinated Silica/Porphyrin Hybrid Nanoparticles with Heavy-Atom Effect for Wide-Field Photodynamic/Photothermal Therapy Using Single Light Source"},"authors":{"en":[{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"},{"name":"Kori Toshinari"},{"name":"Ishimura Kazunori"}],"ja":[{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"},{"name":"松本 俊夫"},{"name":"郡 寿也"},{"name":"石村 和敬"}]},"publication_date":"2014-01-29","publication_name":{"en":"Advanced Functional Materials","ja":"Advanced Functional Materials"},"volume":"Vol.24","number":"No.4","starting_page":"503","ending_page":"513","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/adfm.201301771"],"issn":["1616-3028"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/106068","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24386306","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84891280322&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349631","label":"url"}],"paper_title":{"en":"Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors","ja":"Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors"},"authors":{"en":[{"name":"Harada Takeshi"},{"name":"Ozaki Shuji"},{"name":"Oda Asuka"},{"name":"Tsuji Daisuke"},{"name":"Ikegame Akishige"},{"name":"Iwasa Masami"},{"name":"Udaka Kengo"},{"name":"Fujii Shiroh"},{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kagawa Kumiko"},{"name":"Kuroda Yoshiaki"},{"name":"Kawai Shigeto"},{"name":"Itou Kouji"},{"name":"Yamada-Okabe Hisafumi"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"原田 武志"},{"name":"尾崎 修治"},{"name":"小田 明日香"},{"name":"辻 大輔"},{"name":"池亀 彰茂"},{"name":"岩佐 昌美"},{"name":"宇髙 憲吾"},{"name":"藤井 志朗"},{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"賀川 久美子"},{"name":"黒田 芳明"},{"name":"川合 重人"},{"name":"伊藤 孝司"},{"name":"岡部 尚文"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic \"side population\" in MM cells; and this combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells, and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target drug-resistant MM clonogenic cells.","ja":"The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic \"side population\" in MM cells; and this combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells, and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target drug-resistant MM clonogenic cells."},"publication_date":"2013-12-26","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"Vol.8","number":"No.12","starting_page":"e83905","ending_page":"e83905","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1371/journal.pone.0083905"],"issn":["1932-6203"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/105938","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23708974","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84880304849&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=284313","label":"url"}],"paper_title":{"en":"Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib.","ja":"Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib."},"authors":{"en":[{"name":"Nakamura Shingen"},{"name":"Miki Hirokazu"},{"name":"Kido Shinsuke"},{"name":"Nakano Ayako"},{"name":"Hiasa Masahiro"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"Watanabe Keiichiro"},{"name":"Harada Takeshi"},{"name":"Fujii Shiroh"},{"name":"Takeuchi Kyoko"},{"name":"Kagawa Kumiko"},{"name":"Ozaki Shuji"},{"name":"Matsumoto Toshio"},{"name":"Abe Masahiro"}],"ja":[{"name":"中村 信元"},{"name":"三木 浩和"},{"name":"Kido Shinsuke"},{"name":"Nakano Ayako"},{"name":"日浅 雅博"},{"name":"Oda Asuka"},{"name":"Amou Hiroe"},{"name":"渡邉 佳一郎"},{"name":"Harada Takeshi"},{"name":"藤井 志朗"},{"name":"Takeuchi Kyoko"},{"name":"賀川 久美子"},{"name":"Ozaki Shuji"},{"name":"松本 俊夫"},{"name":"安倍 正博"}]},"description":{"en":"Endoplasmic reticulum (ER) stress is induced in matrix-producing osteoblasts and plays an essential role in osteoblastogenesis. Although the bone anabolic activity of proteasome inhibitors has been demonstrated, the roles of ER stress induced by proteasome inhibition in osteoblastogenesis remain largely unknown. Here we show that bortezomib translationally increases protein levels of activating transcription factor 4 (ATF4), a downstream mediator of ER stress, in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells. The suppression of ATF4 expression by siRNA abrogated osteocalcin expression and mineralized nodule formation by MC3T3-E1 cells induced by bortezomib, indicating a critical role for ATF4 in bortezomib-mediated osteoblastogenesis. However, bortezomib at 20 nM or higher abolished the mineralized nodule formation along with reductions in the expression of osteoblastogenesis mediators β-catenin and Osterix. Furthermore, at 50 nM, bortezomib induced the expression of C/EBP homologous protein (CHOP), suggesting activation of the ATF4-CHOP pro-apoptotic pathway. These results suggest that a low dose of bortezomib induces osteogenic activity, but that, in contrast, excessive ER stress caused by bortezomib at higher doses hampers osteoblastogenesis. Therefore, dosing schedules for proteasome inhibitors warrant further study to maximize anabolic actions without compromising anti-MM activity in patients with multiple myeloma (MM).","ja":"Endoplasmic reticulum (ER) stress is induced in matrix-producing osteoblasts and plays an essential role in osteoblastogenesis. Although the bone anabolic activity of proteasome inhibitors has been demonstrated, the roles of ER stress induced by proteasome inhibition in osteoblastogenesis remain largely unknown. Here we show that bortezomib translationally increases protein levels of activating transcription factor 4 (ATF4), a downstream mediator of ER stress, in bone marrow stromal cells and MC3T3-E1 preosteoblastic cells. The suppression of ATF4 expression by siRNA abrogated osteocalcin expression and mineralized nodule formation by MC3T3-E1 cells induced by bortezomib, indicating a critical role for ATF4 in bortezomib-mediated osteoblastogenesis. However, bortezomib at 20 nM or higher abolished the mineralized nodule formation along with reductions in the expression of osteoblastogenesis mediators β-catenin and Osterix. Furthermore, at 50 nM, bortezomib induced the expression of C/EBP homologous protein (CHOP), suggesting activation of the ATF4-CHOP pro-apoptotic pathway. These results suggest that a low dose of bortezomib induces osteogenic activity, but that, in contrast, excessive ER stress caused by bortezomib at higher doses hampers osteoblastogenesis. Therefore, dosing schedules for proteasome inhibitors warrant further study to maximize anabolic actions without compromising anti-MM activity in patients with multiple myeloma (MM)."},"publication_date":"2013-05-25","publication_name":{"en":"International Journal of Hematology","ja":"International Journal of Hematology"},"volume":"Vol.98","number":"No.1","starting_page":"66","ending_page":"73","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12185-013-1367-z"],"issn":["1865-3774"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23648868","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=264551","label":"url"}],"paper_title":{"en":"Gold Nanoparticle Cluster/Plasmon-Enhanced Fluorescent Silica Core-Shell Nanoparticles for X-Ray Computed Tomography/Fluorescence Dual-Mode Imaging of Tumors","ja":"Gold Nanoparticle Cluster/Plasmon-Enhanced Fluorescent Silica Core-Shell Nanoparticles for X-Ray Computed Tomography/Fluorescence Dual-Mode Imaging of Tumors"},"authors":{"en":[{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"},{"name":"Ishimura Kazunori"}],"ja":[{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"},{"name":"松本 俊夫"},{"name":"石村 和敬"}]},"description":{"en":"Owing to the surface plasmon resonance-enhanced electromagnetic field, clustered gold nanoparticles-fluorescent silica core-shell nanoparticles became excited within the therapeutic window and fluoresced strongly in this window. The nanoparticles enabled tumor detection using fluorescence imaging and X-ray computed tomography.","ja":"Owing to the surface plasmon resonance-enhanced electromagnetic field, clustered gold nanoparticles-fluorescent silica core-shell nanoparticles became excited within the therapeutic window and fluoresced strongly in this window. The nanoparticles enabled tumor detection using fluorescence imaging and X-ray computed tomography."},"publication_date":"2013-04-23","publication_name":{"en":"Chemical Communications","ja":"Chemical Communications"},"volume":"Vol.49","starting_page":"5334","ending_page":"5336","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1039/c3cc41876f"],"issn":["1364-548X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23781284","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-84882252518&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=264550","label":"url"}],"paper_title":{"en":"\"Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia Treatment","ja":"\"Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia Treatment"},"authors":{"en":[{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Sakamoto Wataru"},{"name":"Yogo Toshinobu"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"},{"name":"Ishimura Kazunori"}],"ja":[{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"坂本 渉"},{"name":"余語 利信"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"},{"name":"松本 俊夫"},{"name":"石村 和敬"}]},"description":{"en":"Superparamagnetic nanoparticles (SPIONs) could enable cancer theranostics if magnetic resonance imaging (MRI) and magnetic hyperthermia treatment (MHT) were combined. However, the particle size of SPIONs is smaller than the pores of fenestrated capillaries in normal tissues because superparamagnetism is expressed only at a particle size <10 nm. Therefore, SPIONs leak from the capillaries of normal tissues, resulting in low accumulation in tumors. Furthermore, MHT studies have been conducted in an impractical way: direct injection of magnetic materials into tumor and application of hazardous alternating current (AC) magnetic fields. To accomplish effective enhancement of MRI contrast agents in tumors and inhibition of tumor growth by MHT with intravenous injection and a safe AC magnetic field, we clustered SPIONs not only to prevent their leakage from fenestrated capillaries in normal tissues, but also for increasing their relaxivity and the specific absorption rate. We modified the clusters with folic acid (FA) and polyethylene glycol (PEG) to promote their accumulation in tumors. SPION clustering and cluster modification with FA and PEG were achieved simultaneously via the thiol-ene click reaction. Twenty-four hours after intravenous injection of FA- and PEG-modified SPION nanoclusters (FA-PEG-SPION NCs), they accumulated locally in cancer (not necrotic) tissues within the tumor and enhanced the MRI contrast. Furthermore, 24 h after intravenous injection of the NCs, the mice were placed in an AC magnetic field with H = 8 kA/m and f = 230 kHz (Hf = 1.8×10(9) A/m∙s) for 20 min. The tumors of the mice underwent local heating by application of an AC magnetic field. The temperature of the tumor was higher than the surrounding tissues by ≈6°C at 20 min after treatment. Thirty-five days after treatment, the tumor volume of treated mice was one-tenth that of the control mice. Furthermore, the treated mice were alive after 12 weeks; control mice died up to 8 weeks after treatment.","ja":"Superparamagnetic nanoparticles (SPIONs) could enable cancer theranostics if magnetic resonance imaging (MRI) and magnetic hyperthermia treatment (MHT) were combined. However, the particle size of SPIONs is smaller than the pores of fenestrated capillaries in normal tissues because superparamagnetism is expressed only at a particle size <10 nm. Therefore, SPIONs leak from the capillaries of normal tissues, resulting in low accumulation in tumors. Furthermore, MHT studies have been conducted in an impractical way: direct injection of magnetic materials into tumor and application of hazardous alternating current (AC) magnetic fields. To accomplish effective enhancement of MRI contrast agents in tumors and inhibition of tumor growth by MHT with intravenous injection and a safe AC magnetic field, we clustered SPIONs not only to prevent their leakage from fenestrated capillaries in normal tissues, but also for increasing their relaxivity and the specific absorption rate. We modified the clusters with folic acid (FA) and polyethylene glycol (PEG) to promote their accumulation in tumors. SPION clustering and cluster modification with FA and PEG were achieved simultaneously via the thiol-ene click reaction. Twenty-four hours after intravenous injection of FA- and PEG-modified SPION nanoclusters (FA-PEG-SPION NCs), they accumulated locally in cancer (not necrotic) tissues within the tumor and enhanced the MRI contrast. Furthermore, 24 h after intravenous injection of the NCs, the mice were placed in an AC magnetic field with H = 8 kA/m and f = 230 kHz (Hf = 1.8×10(9) A/m∙s) for 20 min. The tumors of the mice underwent local heating by application of an AC magnetic field. The temperature of the tumor was higher than the surrounding tissues by ≈6°C at 20 min after treatment. Thirty-five days after treatment, the tumor volume of treated mice was one-tenth that of the control mice. Furthermore, the treated mice were alive after 12 weeks; control mice died up to 8 weeks after treatment."},"publication_date":"2013-04-23","publication_name":{"en":"Theranostics","ja":"Theranostics"},"volume":"Vol.3","number":"No.6","starting_page":"366","ending_page":"376","languages":["eng"],"referee":true,"identifiers":{"doi":["10.7150/thno.5860"],"issn":["1838-7640"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=256702","label":"url"}],"paper_title":{"en":"Near-Infrared Fluorescent Silica/Porphyrin Hybrid Nanorings for In Vivo Cancer Imaging","ja":"Near-Infrared Fluorescent Silica/Porphyrin Hybrid Nanorings for In Vivo Cancer Imaging"},"authors":{"en":[{"name":"Hayashi Koichiro"},{"name":"Nakamura Michihiro"},{"name":"Miki Hirokazu"},{"name":"Ozaki Shuji"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"},{"name":"Ishimura Kazunori"}],"ja":[{"name":"林 幸壱朗"},{"name":"中村 教泰"},{"name":"三木 浩和"},{"name":"尾崎 修治"},{"name":"安倍 正博"},{"name":"松本 俊夫"},{"name":"石村 和敬"}]},"publication_date":"2012-09-11","publication_name":{"en":"Advanced Functional Materials","ja":"Advanced Functional Materials"},"volume":"Vol.22","number":"No.17","starting_page":"3539","ending_page":"3546","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/adfm.201200219"],"issn":["1616-3028"]},"published_paper_type":"scientific_journal"},"priority":"input_data"} {"insert":{"user_id":"B000378557","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21902681","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=248823","label":"url"}],"paper_title":{"en":"KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.","ja":"KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts."},"authors":{"en":[{"name":"Miki Hirokazu"},{"name":"Nakamura Shingen"},{"name":"Ozaki Shuji"},{"name":"Oda A"},{"name":"Amou H"},{"name":"Ikegame Akishige"},{"name":"Watanabe Keiichiro"},{"name":"Hiasa Masahiro"},{"name":"Cui Q"},{"name":"Harada T"},{"name":"Fujii Shiroh"},{"name":"Nakano A"},{"name":"Kagawa Kumiko"},{"name":"Takeuchi Kyoko"},{"name":"Yata Ken-ichiro"},{"name":"Sakai A"},{"name":"Abe Masahiro"},{"name":"Matsumoto Toshio"}],"ja":[{"name":"三木 浩和"},{"name":"中村 信元"},{"name":"尾崎 修治"},{"name":"Oda A"},{"name":"Amou H"},{"name":"池亀 彰茂"},{"name":"渡邉 佳一郎"},{"name":"日浅 雅博"},{"name":"Cui Q"},{"name":"Harada T"},{"name":"藤井 志朗"},{"name":"Nakano A"},{"name":"賀川 久美子"},{"name":"竹内 恭子"},{"name":"矢田 健一郎"},{"name":"Sakai A"},{"name":"安倍 正博"},{"name":"松本 俊夫"}]},"description":{"en":"The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM.","ja":"The spicamycin analogue KRN5500 alters glycoprotein processing and induces damage in the endoplasmic reticulum (ER)-Golgi apparatus in cancer cells. In the present study, we explored the cytotoxic effects of KRN5500 on multiple myeloma (MM) cells and the bone marrow microenvironment with special reference to ER stress. Cell proliferation assay showed that KRN5500 induced G1 arrest and apoptosis in MM cells in a time- and dose-dependent manner. KRN5500 enhanced ER stress independently of caspase activation in MM cells. This cell death was observed even in the presence of bone marrow stroma cells or osteoclasts. Notably, KRN5500 induced cell death also in osteoclasts. In vivo effects of KRN5500 were evaluated using two xenograft models established in severe combined immunodeficient (SCID) mice by either subcutaneous injection of RPMI 8226 cells or intra-bone injection of INA-6 cells to subcutaneously implanted rabbit bones (SCID-rab model). KRN5500 significantly inhibited tumour growth in both animal models, and decreased the number of osteoclasts, which resulted in prevention of bone destruction in the SCID-rab model. These results suggest that KRN5500 exerts anti-MM effects through impairing both MM cells and osteoclasts. Therefore, this unique mechanism of KRN5500 might be a useful therapeutic option in patients with MM."},"publication_date":"2011-11","publication_name":{"en":"British Journal of Haematology","ja":"British Journal of Haematology"},"volume":"Vol.155","number":"No.3","starting_page":"328","ending_page":"339","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/j.1365-2141.2011.08844.x"],"issn":["1365-2141"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}